<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM- amlodipine besylate and atorvastatin calcium trihydrate tablet, film coated </strong><br>Ranbaxy Pharmaceuticals Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM TABLETS safely and effectively. See full prescribing information for AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM TABLETS.<br><br> AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM TABLETS, for oral use<br> Initial U.S. Approval: 2004</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col align="left" valign="top" width="75%">
<col align="right" valign="top" width="25%">
<tbody class="Headless">
<tr>
<td align="left">Dosage and Administration (<a href="#S2">2</a>)</td>
<td align="right">10/2012</td>
</tr>
<tr>
<td align="left">Warnings and Precautions / <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (<a href="#S5.1">5.1</a>)</td>
<td align="right">10/2012</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Amlodipine besylate and atorvastatin calcium tablets is a combination of amlodipine besylate, a calcium channel blocker, and atorvastatin calcium, a HMG CoA-reductase inhibitor, indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. </p>
<p class="Highlighta"><span class="Underline">Amlodipine</span> may be used for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (<a href="#S1.1">1.1</a>) and <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span> (<a href="#S1.2">1.2</a>) </p>
<p class="Highlighta"><span class="Underline">Atorvastatin</span> is indicated as an adjunct therapy to diet for prevention of cardiovascular disease (<a href="#S1.3">1.3</a>) and <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> (<a href="#S1.4">1.4</a>) </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><table width="75%">
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rule" align="left"></th>
<th class="Rrule" align="center">Usual starting dose<br>(mg daily)</th>
<th class="Rrule" align="center">Maximum dose<br>(mg daily)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Start small adults or children, fragile, or elderly patients, or patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> on 2.5 mg once daily (<a href="#S2">2</a>)</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Start patients requiring large LDL-C reduction (&gt;45%) at 40 mg once daily (<a href="#S2">2</a>)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Amlodipine</td>
<td class="Rrule" align="center">5<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Atorvastatin</td>
<td class="Rrule" align="center">10–20<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">80</td>
</tr>
</tbody>
</table></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets contain amlodipine besylate equivalent to amlodipine 2.5, 5, or 10 mg and atorvastatin calcium equivalent to atorvastatin 10, 20, 40, or 80 mg (<a href="#S3">3</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Active liver disease (<a href="#S4.1">4.1</a>)</li>
<li>Women who are pregnant or may become pregnant (<a href="#S4.2">4.2</a>)</li>
<li>Nursing mothers (<a href="#S4.3">4.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>: Advise patients to promptly report to their physician unexplained and/or persistent <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Amlodipine besylate and atorvastatin calcium tablet therapy should be discontinued if <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnoses or suspected (<a href="#S5.1">5.1</a>,<a href="#S8.5"> 8.5</a>).</li>
<li>Hepatic transaminitis: Monitor liver enzymes before and during treatment (<a href="#S5.2">5.2</a>).</li>
<li>Assess for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<a href="#S5.4">5.4</a>).</li>
<li>Angina or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> may occur with initiation or dose increase (<a href="#S5.3">5.3</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reaction (3% greater than placebo) to amlodipine is <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (<a href="#S6.1">6.1</a>). </p>
<p class="Highlighta">Most common adverse reactions leading to atorvastatin discontinuation were <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (<a href="#S6.1">6.1</a>). </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Ranbaxy at </span>1-888-726-2299 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="middle" width="50%">
<thead><tr class="First Last"><th align="center" colspan="2">Increased Risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> (<a href="#S2">2</a>,<a href="#S5.1"> 5.1</a>,<a href="#S7"> 7</a>,<a href="#S12.3"> 12.3</a>)</th></tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor (telaprevir)</td>
<td align="left">Avoid atorvastatin</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Lopinavir plus ritonavir</td>
<td align="left">Use lowest dose necessary</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Clarithromycin, itraconazole,<br>HIV protease inhibitors (saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir)</td>
<td align="left">Do not exceed 20 mg atorvastatin daily</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">HIV protease inhibitor (nelfinavir) <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C protease inhibitor (boceprevir)</td>
<td align="left">Do not exceed 40 mg atorvastatin daily</td>
</tr>
</tbody>
</table>
<ul>
<li>Other Lipid-Lowering Medications: Increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (<a href="#S7">7</a>).</li>
<li>Digoxin: Monitor digoxin levels (<a href="#S7.21">7.21</a>).</li>
<li>Oral Contraceptives: Norethindrone and ethinyl estradiol may be increased (<a href="#S7.22">7.22</a>).</li>
<li>Rifampin: Take at same time as amlodipine besylate and atorvastatin calcium tablets (<a href="#S7.20">7.20</a>).</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Plasma concentrations of atorvastatin markedly increased in patients with active liver disease (<a href="#S12.3">12.3</a>).</li></ul></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div>
<div></div>
<div></div>
</div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 6/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2	 <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span> (CAD)</a></h2>
<h2><a href="#section-1.3" class="toc">1.3	Prevention of Cardiovascular Disease</a></h2>
<h2><a href="#section-1.4" class="toc">1.4	<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></a></h2>
<h2><a href="#section-1.5" class="toc">1.5  Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1	Active Liver Disease</a></h2>
<h2><a href="#section-4.2" class="toc">4.2	Pregnancy</a></h2>
<h2><a href="#section-4.3" class="toc">4.3	Nursing Mothers</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Liver Dysfunction</a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Increased Angina and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span> </a></h2>
<h2><a href="#section-5.4" class="toc">5.4  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5  Endocrine Function</a></h2>
<h2><a href="#section-5.6" class="toc">5.6  CNS Toxicity</a></h2>
<h2><a href="#section-5.7" class="toc">5.7  <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">Hemorrhagic Stroke</span></a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1  <span class="Italics"> In Vitro </span>Data</a></h2>
<h2><a href="#section-7.2" class="toc">7.2  Cimetidine</a></h2>
<h2><a href="#section-7.3" class="toc">7.3  Grapefruit Juice</a></h2>
<h2><a href="#section-7.4" class="toc">7.4   Magnesium and Aluminum Hydroxide Antacid</a></h2>
<h2><a href="#section-7.5" class="toc">7.5   Sildenafil</a></h2>
<h2><a href="#section-7.6" class="toc">7.6  Atorvastatin</a></h2>
<h2><a href="#section-7.7" class="toc">7.7  Digoxin</a></h2>
<h2><a href="#section-7.8" class="toc">7.8   Ethanol (alcohol)</a></h2>
<h2><a href="#section-7.9" class="toc">7.9   Warfarin</a></h2>
<h2><a href="#section-7.10" class="toc">7.10  CYP3A4 Inhibitors</a></h2>
<h2><a href="#section-7.11" class="toc">7.11 CYP3A4 Inducers</a></h2>
<h2><a href="#section-7.12" class="toc">7.12  Cyclosporine</a></h2>
<h2><a href="#section-7.13" class="toc">7.13 Drug/Laboratory Test Interactions</a></h2>
<h2><a href="#section-7.14" class="toc">7.14  Strong Inhibitors of CYP3A4</a></h2>
<h2><a href="#section-7.15" class="toc">7.15  Grapefruit Juice</a></h2>
<h2><a href="#section-7.16" class="toc">7.16  Cyclosporine</a></h2>
<h2><a href="#section-7.17" class="toc">7.17  Gemfibrozil</a></h2>
<h2><a href="#section-7.18" class="toc">7.18  Other Fibrates</a></h2>
<h2><a href="#section-7.19" class="toc">7.19  Niacin</a></h2>
<h2><a href="#section-7.20" class="toc">7.20  Rifampin or other Inducers of CYP3A4</a></h2>
<h2><a href="#section-7.21" class="toc">7.21  Digoxin</a></h2>
<h2><a href="#section-7.22" class="toc">7.22  Oral Contraceptives</a></h2>
<h2><a href="#section-7.23" class="toc">7.23  Warfarin</a></h2>
<h2><a href="#section-7.24" class="toc">7.24  Colchicine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2  Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3  Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12   CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2	  Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14  CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Amlodipine for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2	Amlodipine for Chronic Stable Angina</a></h2>
<h2><a href="#section-13.3" class="toc">14.3	Amlodipine for Vasospastic Angina</a></h2>
<h2><a href="#section-13.4" class="toc">14.4	Amlodipine for <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span></a></h2>
<h2><a href="#section-13.5" class="toc">14.5	Amlodipine for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></a></h2>
<h2><a href="#section-13.6" class="toc">14.6	Atorvastatin for Prevention of Cardiovascular Disease</a></h2>
<h2><a href="#section-13.7" class="toc">14.7 Atorvastatin for <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> <span class="Italics">(Fredrickson</span> Types IIa and IIb)</a></h2>
<h2><a href="#section-13.8" class="toc">14.8	Atorvastatin for <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> (<span class="Italics">Fredrickson</span> Type IV)</a></h2>
<h2><a href="#section-13.9" class="toc">14.9	Atorvastatin for Dysbetalipoproteinemia (<span class="Italics">Fredrickson</span> Type III)</a></h2>
<h2><a href="#section-13.10" class="toc">14.10	Atorvastatin for <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></a></h2>
<h2><a href="#section-13.11" class="toc">14.11	Atorvastatin for <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients</a></h2>
<h2><a href="#section-13.12" class="toc">14.12	Amlodipine Besylate and Atorvastatin Calcium Tablets for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> and <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></a></h2>
<h1><a href="#section-14" class="toc">15  REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First">Amlodipine besylate and atorvastatin calcium tablets (amlodipine and atorvastatin) are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate.</p>
<p><span class="Underline">Amlodipine</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">Amlodipine is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. It may be used alone or in combination with other antihypertensive agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	 <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span> (CAD)</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2.1"></a><p></p>
<p class="First"><span class="Underline">Chronic Stable Angina</span></p>
<p>Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2.2"></a><p></p>
<p class="First"><span class="Underline">Vasospastic Angina (Prinzmetal's or <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">Variant Angina</span>)</span></p>
<p>Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2.3"></a><p></p>
<p class="First"><span class="Underline">Angiographically Documented CAD</span></p>
<p>In patients with recently documented CAD by angiography and without <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or an <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> &lt;40%, amlodipine is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2.4"></a><p></p>
<p class="First"><span class="Underline">Atorvastatin</span></p>
<p>Therapy with HMG CoA-reductase inhibitors (lipid-altering agents) should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease from <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin can be started simultaneously with diet restriction.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3	Prevention of Cardiovascular Disease</h2>
<p class="First">In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to:</p>
<ul>
<li>Reduce the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></li>
<li>Reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>Reduce the risk for revascularization procedures and angina </li>
</ul>
<p>In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, smoking, or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, atorvastatin is indicated to:</p>
<ul>
<li>Reduce the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></li>
<li>Reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
</ul>
<p>In patients with clinically evident coronary heart disease, atorvastatin is indicated to:</p>
<ul>
<li>Reduce the risk of non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></li>
<li>Reduce the risk of fatal and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>Reduce the risk for revascularization procedures</li>
<li>Reduce the risk of hospitalization for CHF</li>
<li>Reduce the risk of angina</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.4"></a><a name="section-1.4"></a><p></p>
<h2>1.4	<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></h2>
<p class="First">Atorvastatin is indicated:</p>
<ul>
<li>As an adjunct to diet to reduce elevated total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, and TG levels and to increase HDL-C in patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> (heterozygous familial and nonfamilial) and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> <span class="Italics">(Fredrickson </span>Types IIa and IIb)</li>
<li>As an adjunct to diet for the treatment of patients with elevated serum TG levels <span class="Italics">(Fredrickson </span>Type IV);</li>
<li>For the treatment of patients with primary dysbetalipoproteinemia <span class="Italics">(Fredrickson </span>Type III) who do not respond adequately to diet</li>
<li>To reduce total-C and LDL-C in patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span> as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable</li>
<li>As an adjunct to diet to reduce total-C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span> levels in boys and postmenarchal girls, 10 to 17 years of age, with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> if after an adequate trial of diet therapy the following findings are present:<ol class="LittleAlpha">
<li>LDL-C remains ≥ 190 mg/dL or</li>
<li>LDL-C remains ≥ 160 mg/dL and:<ul class="Disc">
<li> there is a positive family history of premature cardiovascular disease or</li>
<li> two or more other CVD risk factors are present in the pediatric patient</li>
</ul>
</li>
</ol>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.5"></a><a name="section-1.5"></a><p></p>
<h2>1.5  Limitations of Use</h2>
<p class="First">Atorvastatin has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons <span class="Italics">(Fredrickson </span>Types I and V).</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<p class="First"><span class="Underline">Amlodipine besylate and atorvastatin calcium tablets</span></p>
<p>Dosage of amlodipine besylate and atorvastatin calcium tablets must be individualized on the basis of both effectiveness and tolerance for each individual component in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>/angina and <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>. Select doses of amlodipine and atorvastatin independently.</p>
<p>Amlodipine besylate and atorvastatin calcium tablets may be substituted for its individually titrated components. Patients may be given the equivalent dose of amlodipine besylate and atorvastatin calcium tablets or a dose of amlodipine besylate and atorvastatin calcium tablets with increased amounts of amlodipine, atorvastatin, or both for additional antianginal effects, blood pressure lowering, or lipid-lowering effect.</p>
<p>Amlodipine besylate and atorvastatin calcium tablets may be used to provide additional therapy for patients already on one of its components. Amlodipine besylate and atorvastatin calcium tablets may be used to initiate treatment in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> and either <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or angina.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<p class="First"><span class="Underline">Amlodipine</span></p>
<p>The usual initial antihypertensive oral dose of amlodipine is 5 mg once daily, and the maximum dose is 10 mg once daily.</p>
<p>Pediatric (age &gt; 6 years), small adult, fragile, or elderly patients, or patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> may be started on 2.5 mg once daily and this dose may be used when adding amlodipine to other antihypertensive therapy.</p>
<p>Adjust dosage according to blood pressure goals. In general, wait 7 to 14 days between titration steps. Titration may proceed more rapidly, however, if clinically warranted, provided the patient is assessed frequently.</p>
<p><span class="Italics">Angina: </span>The recommended dose of amlodipine for chronic stable or vasospastic angina is 5–10 mg, with the lower dose suggested in the elderly and in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. Most patients will require 10 mg for adequate effect.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary artery disease</span>: </span>The recommended dose range of amlodipine for patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> is 5–10 mg once daily. In clinical studies, the majority of patients required 10 mg <span class="Italics">[see<a href="#S14.4"> Clinical Studies (14.4)</a>]</span>.</p>
<p><span class="Italics">Pediatrics:</span> The effective antihypertensive oral dose of amlodipine in pediatric patients ages 6–17 years is 2.5 mg to 5 mg once daily. Doses in excess of 5 mg daily have not been studied in pediatric patients <span class="Italics">[</span>see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a>,<a href="#S14.1"> Clinical Studies (14.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<p class="First"><span class="Underline">Atorvastatin (<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span>)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> (Fredrickson Types IIa and IIb):</span> The recommended starting dose of atorvastatin is 10 or 20 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily. The dosage range of atorvastatin is 10 to 80 mg once daily. Atorvastatin can be administered as a single dose at any time of the day, with or without food. The starting dose and maintenance doses of atorvastatin should be individualized according to patient characteristics such as goal of therapy and response (see current <span class="Italics">NCEP Guidelines</span>). After initiation and/or upon titration of atorvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span>:</span> The dosage range of atorvastatin in patients with homozygous FH is 10 to 80 mg daily. Atorvastatin should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.3"></a><p></p>
<p class="First"><span class="Italics">Concomitant Lipid-Lowering Therapy: </span>Atorvastatin may be used with bile acid resins. Monitor for signs of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> in patients receiving the combination of HMG-CoA reductase inhibitors (statins) and fibrates <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>,<a href="#S7"> Drug Interactions (7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.4"></a><p></p>
<p class="First"><span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal disease</span> does not affect the plasma concentrations nor LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>,<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.5"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="Italics">Use with Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors:</span> In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor (telaprevir), avoid therapy with atorvastatin. In patients with HIV taking lopinavir plus ritonavir, use the lowest necessary dose of atorvastatin. <span class="XmChange">In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, limit therapy with  atorvastatin to 20 mg, and make appropriate clinical assessment to ensure that the lowest dose necessary of atorvastatin is employed. In patients taking the HIV protease inhibitor nelfinavir or the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor boceprevir, limit therapy with atorvastatin to 40 mg, and make appropriate clinical assessment to ensure that the lowest dose necessary of atorvastatin is employed <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>,<a href="#S7.13"> Drug Interactions (7.13)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.6"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients (10–17 years of age):</span> The recommended starting dose of atorvastatin is 10 mg/day; the maximum recommended dose is 20 mg/day (doses greater than 20 mg have not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy <span class="Italics">[see current NCEP Pediatric Panel Guidelines <span class="Sup">1</span>,<a href="#S15"> (References (15)</a>,<a href="#S12"> Clinical Pharmacology (12)</a>, and<a href="#S1.4"> Indications and Usage (1.4)</a>]</span>. Adjustments should be made at intervals of 4 weeks or more.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Amlodipine besylate and atorvastatin calcium tablets are formulated for oral administration in the following strength combinations:</p>
<table width="50%">
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" colspan="2" rowspan="2"></th>
<th class="Lrule" align="left" colspan="4">Atorvastatin (mg)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">10</th>
<th class="Rrule" align="center">20</th>
<th class="Rrule" align="center">40</th>
<th class="Rrule" align="center">80</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" rowspan="3">Amlodipine<br>(mg)</td>
<td class="Rrule" align="left">2.5</td>
<td class="Rrule" align="center">X</td>
<td class="Rrule" align="center">X</td>
<td class="Rrule" align="center">X</td>
<td class="Rrule" align="center">--</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">5</td>
<td class="Rrule" align="center">X</td>
<td class="Rrule" align="center">X</td>
<td class="Rrule" align="center">X</td>
<td class="Rrule" align="center">X</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">10</td>
<td class="Rrule" align="center">X</td>
<td class="Rrule" align="center">X</td>
<td class="Rrule" align="center">X</td>
<td class="Rrule" align="center">X</td>
</tr>
</tbody>
</table>
<p>Combinations of atorvastatin with 2.5 mg and 5 mg amlodipine are film-coated white, and combinations of atorvastatin with 10 mg amlodipine are film-coated blue.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1	Active Liver Disease</h2>
<p class="First">Atorvastatin is contraindicated in patients with active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels <span class="Italics">[see<a href="#S5.2"> Warnings and Precautions 5.2 </a>and<a href="#S12.3"> Clinical Pharmacology 12.3</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2	Pregnancy</h2>
<p class="First">Atorvastatin is contraindicated in women who are pregnant or may become pregnant. Atorvastatin may cause fetal harm when administered to a pregnant woman. Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> derivatives are essential for fetal development. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>.</p>
<p>There are no adequate and well-controlled studies of atorvastatin use during pregnancy; however, in rare reports congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. Amlodipine besylate and atorvastatin calcium tablets should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazard. If the patient becomes pregnant while taking this drug, therapy should be discontinued immediately and the patient apprised of the potential hazard to the fetus <span class="Italics">[see<a href="#S8.1"> Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.3"></a><a name="section-4.3"></a><p></p>
<h2>4.3	Nursing Mothers</h2>
<p class="First">It is not known whether atorvastatin or amlodipine are excreted into human milk; however, a small amount of another statin does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women taking amlodipine besylate and atorvastatin calcium tablets should not breastfeed their infants <span class="Italics">[see<a href="#S8.3"> Specific Populations (8.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1  <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></h2>
<p class="First">Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> have been reported with atorvastatin and with other drugs in this class. A history of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> may be a risk factor for the development of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. Such patients merit closer monitoring for skeletal muscle effects.</p>
<p>Atorvastatin, like other statins, occasionally causes <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, defined as <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span> or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in conjunction with increases in creatine phosphokinase (CPK) values &gt;10 times upper limit of normal [ULN]. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p style="border-left:1px solid;"><span class="XmChange">There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (IMNM), an autoimmune <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, associated with statin use. IMNM is characterized by: proximal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> without significant <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>; improvement with immunosuppressive agents.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> should be considered in any patient with diffuse <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, muscle <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or marked elevation of CPK. Patients should be advised to report promptly unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if muscle signs and symptoms persist after discontinuing Amlodipine besylate and atorvastatin calcium tablets. Amlodipine besylate and atorvastatin calcium tablets therapy should be discontinued if markedly elevated CPK levels occur or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with statins is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir, niacin, or azole antifungals.</span> Physicians considering combined therapy with amlodipine besylate and atorvastatin calcium tablets and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir,  fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs <span class="Italics">[see<a href="#S7.13"> Drug Interactions (7.13)</a>]</span>. Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. 								</p>
<p>Prescribing recommendations for interacting agents are summarized in Table 2 <span class="Italics">[see also<a href="#S2"> Dosage and Administration (2)</a>,<a href="#S7.13"> Drug Interactions (7.13)</a>,<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
<a name="table2"></a><table width="50%">
<caption><span>Table 2. Atorvastatin Drug Interactions Associated with Increased Risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></span></caption>
<col align="left" valign="top" width="50%">
<col align="left" valign="middle" width="50%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Use with caution and with the lowest dose necessary (<a href="#S12.3">12.3</a>)</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Rrule" align="left">Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor (telaprevir)</td>
<td align="left">Avoid atorvastatin</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">HIV protease inhibitor (lopinavir plus ritonavir)</td>
<td align="left">Use with caution and lowest dose necessary</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Clarithromycin, itraconazole,<br>HIV protease inhibitors (saquinavir plus ritonavir<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>,  darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir)</td>
<td align="left">Do not exceed 20 mg atorvastatin daily</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">												HIV protease inhibitor (nelfinavir)<br><span class="XmChange"> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C protease inhibitor (boceprevir)</span>
</td>
<td align="left">Do not exceed 40 mg atorvastatin daily</td>
</tr>
</tbody>
</table>
<p>Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine [see<span class="Italics"><a href="#S7.23"> Drug Interactions (7.23)</a></span>].</p>
<p>Withhold or discontinue in any patient with an acute, serious condition suggestive of a <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> or having a risk factor predisposing to the development of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (e.g., severe acute <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; major surgery; <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>; severe metabolic, endocrine, and electrolyte disorders; and uncontrolled <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Liver Dysfunction</h2>
<p class="First">Statins, like atorvastatin, and some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (&gt;3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.</p>
<p>One patient in clinical trials with atorvastatin developed <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. Increases in liver function tests (LFT) in other patients were not associated with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae. Eighteen of 30 patients with persistent LFT elevations continued treatment with a reduced dose of atorvastatin.</p>
<p>It is recommended that liver enzyme tests be obtained prior to initiating therapy with atorvastatin and repeated as clinically indicated. There have been rare postmarketing reports of fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients taking statins, including atorvastatin. If serious <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> with clinical symptoms and/or <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs during treatment with amlodipine besylate and atorvastatin calcium tablets, promptly interrupt therapy. If an alternate etiology is not found, do not restart amlodipine besylate and atorvastatin calcium tablets.</p>
<p>Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of amlodipine besylate and atorvastatin calcium tablets <span class="Italics">[see<a href="#S4.1"> Contraindications (4.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3  Increased Angina and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span> </h2>
<p class="First">Worsening angina and <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> can develop after starting or increasing the dose of amlodipine, particularly in patients with severe obstructive <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is possible with use of amlodipine, particularly in patients with severe <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span>. Because of the gradual onset of action, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">acute hypotension</span> is unlikely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5  Endocrine Function</h2>
<p class="First">Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including atorvastatin.</p>
<p>Statins interfere with <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and theoretically might blunt adrenal and/or gonadal steroid production. Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown. Avoid a statin with drugs that may decrease the levels or activity of endogenous steroid hormones such as ketoconazole, spironolactone, and cimetidine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6  CNS Toxicity</h2>
<p class="First">Brain <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> was seen in a female dog treated with atorvastatin for 3 months at 120 mg/kg/day. Brain <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day. The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0–24 hours) based on the maximum human dose of 80 mg/day. A single <span class="product-label-link" type="condition" conceptid="4198075" conceptname="Tonic seizure">tonic convulsion</span> was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day. These doses were</p>
<p>6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0–24) based on the maximum recommended human dose of 80 mg/day.</p>
<p>CNS vascular lesions, characterized by perivascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other statins. A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7  <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">Hemorrhagic Stroke</span></h2>
<p class="First">In a post-hoc analysis of the <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Prevention by Aggressive Reduction in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels (SPARCL) study where atorvastatin 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA within the preceding 6 months, a higher incidence of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was seen in the atorvastatin 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively). The incidence of non-fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%). Some baseline characteristics, including hemorrhagic and lacunar <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> on study entry, were associated with a higher incidence of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> in the atorvastatin group <span class="Italics">[see<a href="#S6.1"> Adverse Reactions (6.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the label:</p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> and <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>
</dd>
<dt> </dt>
<dd>Liver enzyme abnormalities <span class="Italics">[see<a href="#S5.2"> Warnings and Precautions (5.2)</a>]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Amlodipine besylate and atorvastatin calcium tablets</span></p>
<p>Amlodipine besylate/atorvastatin calcium tablets have been evaluated for safety in 1,092 patients in double-blind placebo-controlled studies treated for co-morbid <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. In general, treatment with amlodipine besylate and atorvastatin calcium tablets was well tolerated. For the most part, adverse reactions have been mild or moderate in severity. In clinical trials with amlodipine besylate and atorvastatin calcium tablets, no adverse reactions peculiar to this combination have been observed. Adverse reactions are similar in terms of nature, severity, and frequency to those reported previously with amlodipine and atorvastatin.</p>
<p>The following information is based on the clinical experience with amlodipine and atorvastatin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline">Amlodipine </span></p>
<p>Amlodipine has been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials. In general, treatment with amlodipine was well tolerated at doses up to 10 mg daily. Most adverse reactions reported during therapy with amlodipine were of mild or moderate severity. In controlled clinical trials directly comparing amlodipine (N=1,730) at doses up to 10 mg to placebo (N=1,250), discontinuation of amlodipine because of adverse reactions was required in only about 1.5% of patients and was not significantly different from placebo (about 1%). The most commonly reported side effects more frequent than placebo are <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. The incidence (%) of side effects that occurred in a dose-related manner are as follows:</p>
<table width="75%">
<col align="left" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center">2.5 mg<br>N=275</th>
<th align="center">Amlodipine<br>5 mg<br>N=296</th>
<th align="center">10 mg<br>N=268</th>
<th align="center">Placebo<br>N=520</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td align="center">1.8</td>
<td align="center">3.0</td>
<td align="center">10.8</td>
<td align="center">0.6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">1.1</td>
<td align="center">3.4</td>
<td align="center">3.4</td>
<td align="center">1.5</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td align="center">0.7</td>
<td align="center">1.4</td>
<td align="center">2.6</td>
<td align="center">0.0</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td align="center">0.7</td>
<td align="center">1.4</td>
<td align="center">4.5</td>
<td align="center">0.6</td>
</tr>
</tbody>
</table>
<p>Other adverse reactions that were not clearly dose related but were reported at an incidence greater than 1.0% in placebo-controlled clinical trials include the following:</p>
<table width="75%">
<col align="left" valign="bottom" width="33%">
<col align="center" valign="bottom" width="34%">
<col align="center" valign="bottom" width="33%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center">Amlodipine (%)<br>(N=1730)</th>
<th align="center">Placebo (%)<br>(N=1250)</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">4.5</td>
<td align="center">2.8</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">2.9</td>
<td align="center">1.9</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="center">1.6</td>
<td align="center">0.3</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">1.4</td>
<td align="center">0.6</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> appear to be more common in women than in men.</p>
<p>The following events occurred in &lt;1% but &gt;0.1% of patients treated with amlodipine in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship:</p>
<p>Cardiovascular: <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> (including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p>Central and Peripheral Nervous System: <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy peripheral</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>,  <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gingival <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>.</p>
<p>General: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>,<a name="footnote-reference-4" href="#footnote-4" class="Sup">1</a> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>.</p>
<p>Musculoskeletal System: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>,<a href="#footnote-4" class="Sup">1</a> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
<p>Psychiatric: <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> (male<a href="#footnote-4" class="Sup">1</a> and female), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>.</p>
<p>Respiratory System: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>,<a href="#footnote-4" class="Sup">1</a> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>.</p>
<p>Skin and Appendages: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>,<a href="#footnote-4" class="Sup">1</a> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>,<a href="#footnote-4" class="Sup">1</a> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculopapular.</p>
<p>Special Senses: <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p>Urinary System: micturition frequency, micturition disorder, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>.</p>
<p>Autonomic Nervous System: <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>.</p>
<p>Metabolic and Nutritional: <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>.</p>
<p>Hemopoietic: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p>Amlodipine therapy has not been associated with clinically significant changes in routine laboratory tests. No clinically relevant changes were noted in serum potassium, serum glucose, total triglycerides, total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, uric acid, blood urea nitrogen, or creatinine.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">1</a></dt>
<dd>These events occurred in less than 1% in placebo-controlled trials, but the incidence of these side effects was between 1% and 2% in all multiple dose studies.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Underline">Atorvastatin</span></p>
<p>In the atorvastatin placebo-controlled clinical trial database of 16,066 patients (8,755 atorvastatin vs. 7,311 placebo; age range 10–93 years, 39% women, 91% Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 9.7% of patients on atorvastatin and 9.5% of the patients on placebo discontinued because of adverse reactions regardless of causality. The five most common adverse reactions in patients treated with atorvastatin that led to treatment discontinuation and occurred at a rate greater than placebo were: <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (0.7%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (0.5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.4%), <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increase (0.4%), and hepatic enzyme increase (0.4%).</p>
<p>The most commonly reported adverse reactions (incidence ≥ 2% and greater than placebo) regardless of causality, in patients treated with atorvastatin in placebo-controlled trials (n=8,755) were: <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (8.3%), <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (6.9%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (6.8%), <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span> (6.0%), and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (5.7%).</p>
<p>Table 3 summarizes the frequency of clinical adverse reactions, regardless of causality, reported in ≥ 2% and at a rate greater than placebo in patients treated with atorvastatin (n=8,755), from seventeen placebo-controlled trials.</p>
<table width="75%">
<caption><span>Table 3. Clinical Adverse Reactions Occurring in ≥ 2% in Patients Treated with Any Dose of Atorvastatin and at an Incidence Greater than Placebo Regardless of Causality (% of Patients)</span></caption>
<col align="left" valign="top" width="16%">
<col align="left" valign="middle" width="14%">
<col align="left" valign="middle" width="14%">
<col align="left" valign="middle" width="14%">
<col align="left" valign="middle" width="14%">
<col align="left" valign="middle" width="14%">
<col align="left" valign="middle" width="14%">
<thead><tr class="First Last">
<th class="Lrule" align="left" valign="middle">Adverse Reaction<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</th>
<th align="left">Any dose<br>N=8755</th>
<th align="left">10 mg<br>N=3908</th>
<th align="left">20 mg<br>N=188</th>
<th align="left">40 mg<br>N=604</th>
<th align="left">80 mg<br>N=4055</th>
<th class="Rrule" align="left">Placebo<br>N=7311</th>
</tr></thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Adverse Reaction ≥ 2% in any dose greater than placebo.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td align="left">8.3</td>
<td align="left">12.9</td>
<td align="left">5.3</td>
<td align="left">7.0</td>
<td align="left">4.2</td>
<td class="Rrule" align="left">8.2</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="left">6.9</td>
<td align="left">8.9</td>
<td align="left">11.7</td>
<td align="left">10.6</td>
<td align="left">4.3</td>
<td class="Rrule" align="left">6.5</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left">6.8</td>
<td align="left">7.3</td>
<td align="left">6.4</td>
<td align="left">14.1</td>
<td align="left">5.2</td>
<td class="Rrule" align="left">6.3</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td align="left">6.0</td>
<td align="left">8.5</td>
<td align="left">3.7</td>
<td align="left">9.3</td>
<td align="left">3.1</td>
<td class="Rrule" align="left">5.9</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td align="left">5.7</td>
<td align="left">6.9</td>
<td align="left">6.4</td>
<td align="left">8.0</td>
<td align="left">4.1</td>
<td class="Rrule" align="left">5.6</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="left">4.7</td>
<td align="left">5.9</td>
<td align="left">3.2</td>
<td align="left">6.0</td>
<td align="left">3.3</td>
<td class="Rrule" align="left">4.3</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="left">4.0</td>
<td align="left">3.7</td>
<td align="left">3.7</td>
<td align="left">7.1</td>
<td align="left">3.8</td>
<td class="Rrule" align="left">3.5</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td align="left">3.8</td>
<td align="left">5.2</td>
<td align="left">3.2</td>
<td align="left">5.1</td>
<td align="left">2.3</td>
<td class="Rrule" align="left">3.6</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td align="left">3.6</td>
<td align="left">4.6</td>
<td align="left">4.8</td>
<td align="left">5.1</td>
<td align="left">2.4</td>
<td class="Rrule" align="left">3.0</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="left">3.5</td>
<td align="left">3.6</td>
<td align="left">5.9</td>
<td align="left">8.4</td>
<td align="left">2.7</td>
<td class="Rrule" align="left">3.1</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="left">3.0</td>
<td align="left">2.8</td>
<td align="left">1.1</td>
<td align="left">5.3</td>
<td align="left">2.8</td>
<td class="Rrule" align="left">2.9</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td align="left">2.3</td>
<td align="left">3.9</td>
<td align="left">1.6</td>
<td align="left">2.8</td>
<td align="left">0.7</td>
<td class="Rrule" align="left">2.1</td>
</tr>
</tbody>
</table>
<p>Other adverse reactions reported in placebo-controlled studies include:   </p>
<p><span class="Italics">Body as a whole:</span> <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>; <span class="Italics">Digestive system: </span><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>; <span class="Italics">Musculoskeletal system</span>: <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="4214612" conceptname="Muscle fatigue">muscle fatigue</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>; <span class="Italics">Metabolic and nutritional system:</span> transaminases increase, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function test abnormal</span>, blood alkaline phosphatase increase, creatine phosphokinase increase, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>; <span class="Italics">Nervous system:</span> <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmare</span>; <span class="Italics">Respiratory system: </span><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>; <span class="Italics">Skin and appendages:</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; <span class="Italics">Special senses:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; <span class="Italics">Urogenital system:</span> white blood cells urine positive.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Italics">Treating to New Targets Study (TNT)</span></p>
<p>In TNT <span class="Italics">[see<a href="#S14.6"> Clinical Studies (14.6)</a>]</span> involving 10,001 subjects (age range 29–78 years, 19% women; 94.1% Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident CHD treated with atorvastatin 10 mg daily (n=5,006) or atorvastatin 80 mg daily (n=4,995), serious adverse reactions and discontinuations because of adverse reactions increased with dose. Persistent transaminase elevations (≥3 × ULN twice within 4–10 days) occurred in 62 (1.3%) individuals with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg. Elevations of CK (≥ 10 × ULN) were low overall, but were higher in the high-dose atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin group (6, 0.1%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Prevention by Aggressive Reduction in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels (SPARCL)</span></p>
<p>In SPARCL involving 4,731 subjects (age range 21–92 years, 40% women; 93.3% Caucasians, 3.0% Blacks, 0.6% Asians, 3.1% other) without clinically evident CHD but with a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or transient ischemic attack (TIA) within the previous 6 months treated with atorvastatin 80 mg (n=2,365) or placebo (n=2,366) for a median follow-up of 4.9 years, there was a higher incidence of persistent hepatic transaminase elevations (≥ 3 × ULN twice within 4–10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%). Elevations of CK (&gt;10 × ULN) were rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%). <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> was reported as an adverse reaction in 144 subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo group <span class="Italics">[see Warnings and Precautions (5.8)]</span>.</p>
<p>In a post-hoc analysis, atorvastatin 80 mg reduced the incidence of <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> (218/2365, 9.2% vs. 274/2366, 11.6%) and increased the incidence of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> (55/2365, 2.3% vs. 33/2366, 1.4%) compared to placebo. The incidence of fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was similar between groups (17 atorvastatin vs. 18 placebo). The incidence of non-fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span> was significantly greater in the atorvastatin group (38 non-fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>) as compared to the placebo group (16 non-fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>). Subjects who entered the study with a <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> appeared to be at increased risk for <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> [7 (16%) atorvastatin vs. 2 (4%) placebo].</p>
<p>There were no significant differences between the treatment groups for all-cause mortality: 216 (9.1%) in the atorvastatin 80 mg/day group vs. 211 (8.9%) in the placebo group. The proportions of subjects who experienced cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were numerically smaller in the atorvastatin 80 mg group (3.3%) than in the placebo group (4.1%). The proportions of subjects who experienced non-cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were numerically larger in the atorvastatin 80 mg group (5.0%) than in the placebo group (4.0%).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5.1"></a><p></p>
<p class="First"><span class="Underline">Pediatrics:</span> In a 26-week controlled study in boys and postmenarchal girls (n=140, 31% female; 92% Caucasians, 1.6% Blacks, 1.6% Asians, 4.8% other), the safety and tolerability profile of atorvastatin 10 to 20 mg daily was generally similar to that of placebo <span class="Italics">[see<a href="#S14.11"> Clinical Studies (14.11) </a>and<a href="#S8.4"> Use in Specific Populations (8.4)</a>]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval of amlodipine and atorvastatin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<p class="First"><span class="Underline">Amlodipine</span></p>
<p>The following postmarketing event has been reported infrequently where a causal relationship is uncertain: <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>. In postmarketing experience, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and hepatic enzyme elevations (mostly consistent with <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>), in some cases severe enough to require hospitalization, have been reported in association with use of amlodipine.</p>
<p>Amlodipine has been used safely in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>, well-compensated <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and <span class="product-label-link" type="condition" conceptid="4042056" conceptname="Lipids abnormal">abnormal lipid profiles</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<p class="First"><span class="Underline">Atorvastatin</span></p>
<p>Adverse reactions associated with atorvastatin therapy reported since market introduction that are not listed above, regardless of causality assessment, include the following: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous rashes</span> (including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>), <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p>There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with statin use [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
<p>There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> (e.g., <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">forgetfulness</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<p class="First">Data from a drug-drug interaction study involving 10 mg of amlodipine and 80 mg of atorvastatin in healthy subjects indicate that the pharmacokinetics of amlodipine are not altered when the drugs are co-administered. The effect of amlodipine on the pharmacokinetics of atorvastatin showed no effect on the Cmax: 91% (90% confidence interval: 80 to 103%), but the AUC of atorvastatin increased by 18% (90% confidence interval: 109 to 127%) in the presence of amlodipine, which is not clinically meaningful.</p>
<p>No drug interaction studies have been conducted with amlodipine besylate and atorvastatin calcium tablets and other drugs, although studies have been conducted in the individual amlodipine and atorvastatin components, as described below:</p>
<p><span class="Underline">Amlodipine</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1  <span class="Italics"> In Vitro </span>Data</h2>
<p class="First"><span class="Italics"> In vitro</span> data in human plasma indicate that amlodipine has no effect on the protein binding of drugs tested (digoxin, phenytoin, warfarin, and indomethacin).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2  Cimetidine</h2>
<p class="First">Co-administration of amlodipine with cimetidine did not alter the pharmacokinetics of amlodipine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3  Grapefruit Juice</h2>
<p class="First">Co-administration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4   Magnesium and Aluminum Hydroxide Antacid</h2>
<p class="First">Co-administration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine had no significant effect on the pharmacokinetics of amlodipine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5   Sildenafil</h2>
<p class="First">A single 100 mg dose of sildenafil in subjects with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> had no effect on the pharmacokinetic parameters of amlodipine. When amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6  Atorvastatin</h2>
<p class="First">Co-administration of multiple 10 mg doses of amlodipine with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.7"></a><a name="section-7.7"></a><p></p>
<h2>7.7  Digoxin</h2>
<p class="First">Co-administration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.8"></a><a name="section-7.8"></a><p></p>
<h2>7.8   Ethanol (alcohol)</h2>
<p class="First">Single and multiple 10 mg doses of amlodipine had no significant effect on the pharmacokinetics of ethanol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.9"></a><a name="section-7.9"></a><p></p>
<h2>7.9   Warfarin</h2>
<p class="First">Co-administration of amlodipine with warfarin did not change the warfarin <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> response time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.10"></a><a name="section-7.10"></a><p></p>
<h2>7.10  CYP3A4 Inhibitors</h2>
<p class="First">Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. Erythromycin co-administration in healthy volunteers did not significantly change amlodipine systemic exposure. However, strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) may increase the plasma concentrations of amlodipine to a greater extent. Monitor for symptoms of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> when amlodipine is co-administered with CYP3A4 inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.11"></a><a name="section-7.11"></a><p></p>
<h2>7.11 CYP3A4 Inducers</h2>
<p class="First">No information is available on the quantitative effects of CYP3A4 inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A4 inducers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.12"></a><a name="section-7.12"></a><p></p>
<h2>7.12  Cyclosporine</h2>
<p class="First">A prospective study in renal transplant patients (N=11) showed on an average of 40% increase in trough cyclosporine levels when concomitantly treated with amlodipine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.13"></a><a name="section-7.13"></a><p></p>
<h2>7.13 Drug/Laboratory Test Interactions</h2>
<p class="First">None known.</p>
<p><span class="Underline">Atorvastatin</span></p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1) </a>and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.14"></a><a name="section-7.14"></a><p></p>
<h2>7.14  Strong Inhibitors of CYP3A4</h2>
<p class="First">Atorvastatin is metabolized by CYP3A4. Concomitant administration of atorvastatin with strong inhibitors of CYP3A4 can lead to increases in plasma concentrations of atorvastatin. The extent of interaction and potentiation of effects depend on the variability of effect on CYP3A4.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.14.1"></a><p></p>
<p class="First"><span class="Italics">Clarithromycin:</span> Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 80 mg with clarithromycin (500 mg twice daily) compared to that of atorvastatin alone <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>. Therefore, in patients taking clarithromycin, avoid atorvastatin doses &gt;20 mg <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions, Skeletal Muscle (5.1) </a>and<a href="#S2"> Dosage and Administration (2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.14.2"></a><p></p>
<p class="First"><span class="Italics">Combination of Protease Inhibitors:</span> Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin with several combinations of HIV protease inhibitors, as well as with the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor telaprevir,  compared to that of atorvastatin alone <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>. Therefore, in patients taking the HIV protease inhibitor tipranavir plus ritonavir, or the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor telaprevir, concomitant use of atorvastatin should be avoided. In patients taking the HIV protease inhibitor lopinavir plus ritonavir, caution should be used when prescribing atorvastatin and the lowest dose necessary should be used. In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of atorvastatin should not exceed 20 mg  <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1) </a>and<a href="#S2"> Dosage and Administration (2)</a>]</span>. In patients taking the HIV protease inhibitor nelfinavir or the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor boceprevir, the dose of atorvastatin should not exceed 40 mg and close clinical monitoring is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.14.3"></a><p></p>
<p class="First"><span class="Italics">Itraconazole</span><span class="Italics">: </span>Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 40 mg and itraconazole 200 mg <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>. Therefore, in patients taking itraconazole, avoid atorvastatin doses &gt;20 mg <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1) </a>and<a href="#S2"> Dosage and Administration (2)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.15"></a><a name="section-7.15"></a><p></p>
<h2>7.15  Grapefruit Juice</h2>
<p class="First">Contains one or more components that inhibit CYP3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (&gt;1.2 liters per day).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.16"></a><a name="section-7.16"></a><p></p>
<h2>7.16  Cyclosporine</h2>
<p class="First">Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 10 mg and cyclosporine 5.2 mg/kg/day compared to that of atorvastatin alone <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>. The co-administration of atorvastatin with cyclosporine should be avoided <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.17"></a><a name="section-7.17"></a><p></p>
<h2>7.17  Gemfibrozil</h2>
<p class="First">Because of an increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> when HMG-CoA reductase inhibitors are co-administered with gemfibrozil, avoid concomitant administration of atorvastatin with gemfibrozil [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.18"></a><a name="section-7.18"></a><p></p>
<h2>7.18  Other Fibrates</h2>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates. [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.19"></a><a name="section-7.19"></a><p></p>
<h2>7.19  Niacin</h2>
<p class="First">The risk of skeletal muscle effects may be enhanced when atorvastatin is used in combination with niacin; consider a reduction in atorvastatin dosage in this setting [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.20"></a><a name="section-7.20"></a><p></p>
<h2>7.20  Rifampin or other Inducers of CYP3A4</h2>
<p class="First">Concomitant administration of atorvastatin with inducers of CYP3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Because of the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.21"></a><a name="section-7.21"></a><p></p>
<h2>7.21  Digoxin</h2>
<p class="First">When multiple doses of atorvastatin and digoxin were co-administered, steady-state plasma digoxin concentrations increased by approximately 20%. Monitor digoxin levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.22"></a><a name="section-7.22"></a><p></p>
<h2>7.22  Oral Contraceptives</h2>
<p class="First">Co-administration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol ) <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>. Consider these increases when selecting an oral contraceptive for a woman taking amlodipine besylate and atorvastatin calcium tablets.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.23"></a><a name="section-7.23"></a><p></p>
<h2>7.23  Warfarin</h2>
<p class="First">Atorvastatin had no clinically significant effect on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time when administered to patients receiving chronic warfarin treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.24"></a><a name="section-7.24"></a><p></p>
<h2>7.24  Colchicine</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with atorvastatin co-administered with colchicine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category X <span class="Italics">[see<a href="#S4.2"> Contraindications (4.2)</a>]</span></p>
<p>Atorvastatin is contraindicated in women who are pregnant or may become pregnant. Atorvastatin may cause fetal harm when administered to a pregnant woman. Amlodipine besylate and atorvastatin calcium tablets should be administered to women of child bearing potential only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the woman becomes pregnant while taking amlodipine besylate and atorvastatin calcium tablets, it should be discontinued immediately and the patient advised again as to the potential hazards to the fetus, and the lack of known clinical benefit with continued use during pregnancy.</p>
<p>Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> products are essential for fetal development. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Underline">Amlodipine</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. Amlodipine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or other embryo/fetal toxicity was found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses up to 10 mg amlodipine/kg/day (respectively, 8 times <a name="footnote-reference-6" href="#footnote-6" class="Sup">2</a> and 23 times <a href="#footnote-6" class="Sup">2</a> the maximum recommended human dose of 10 mg on a mg/m<span class="Sup">2</span> basis) during their respective periods of major organogenesis. However, litter size was significantly decreased (by about 50%) and the number of intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> was significantly increased (about 5-fold) in rats receiving amlodipine maleate at a dose equivalent to 10 mg amlodipine/kg/day for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong both the gestation period and the duration of labor in rats at this dose.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">2</a></dt>
<dd>Based on patient weight of 50 kg.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.3"></a><p></p>
<p class="First"><span class="Underline">Atorvastatin</span></p>
<p>There are no adequate and well-controlled studies of atorvastatin use during pregnancy. There have been rare reports of congenital anomalies following intrauterine exposure to statins. In a review of about 100 prospectively followed pregnancies in women exposed to other statins, the incidences of congenital anomalies, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>, and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>/<span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> did not exceed the rate expected in the general population. However, this study was only able to exclude a three to four-fold increased risk of congenital anomalies over background incidence. In 89% of these cases, drug treatment started before pregnancy and stopped during the first trimester when pregnancy was identified.</p>
<p>Atorvastatin crosses the rat placenta and reaches a level in fetal liver equivalent to that of maternal plasma. Atorvastatin was not teratogenic in rats at doses up to 300 mg/kg/day or in rabbits at doses up to 100 mg/kg/day. These doses resulted in multiples of about 30 times (rat) or 20 times (rabbit) the human exposure based on surface area (mg/m<span class="Sup">2</span>) <span class="Italics">[see<a href="#S4.2"> Contraindications (4.2)</a>].</span></p>
<p>In a study in rats given atorvastatin calcium at doses equivalent to 20, 100, or 225 mg/kg/day, from gestation day 7 through to lactation day 21 (weaning), there was decreased pup survival at birth, neonate, weaning, and maturity in pups of mothers dosed with 225 mg/kg/day. Body weight was decreased on days 4 and 21 in pups of mothers dosed at 100 mg/kg/day; pup body weight was decreased at birth and at days 4, 21, and 91 at 225 mg/kg/day. Pup development was delayed (rotorod performance at 100 mg/kg/day and acoustic startle at 225 mg/kg/day; pinnae detachment and eye-opening at 225 mg/kg/day). These doses of atorvastatin correspond to 6 times (100 mg/kg) and 22 times (225 mg/kg) the human AUC at 80 mg/day.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2  Labor and Delivery</h2>
<p class="First">No studies have been conducted in pregnant women on the effect of amlodipine besylate and atorvastatin calcium tablets, amlodipine, or atorvastatin on the mother or the fetus during labor or delivery, or on the duration of labor or delivery. Amlodipine has been shown to prolong the duration of labor in rats.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3  Nursing Mothers</h2>
<p class="First">It is not known whether amlodipine is excreted in human milk. In the absence of this information, it is recommended that nursing be discontinued while amlodipine besylate and atorvastatin calcium tablets are administered.</p>
<p>It is not known whether atorvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk. Nursing rat pups had plasma and liver drug levels of 50% and 40%, respectively, of that in their mother's milk. Animal breast milk drug levels may not accurately reflect human breast milk levels. Because another drug in this class passes into human milk and because statins have a potential to cause serious adverse reactions in nursing infants, women taking amlodipine besylate and atorvastatin calcium tablets should be advised not to nurse their infants <span class="Italics">[see<a href="#S4.3"> Contraindications (4.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">The safety and effectiveness of amlodipine besylate and atorvastatin calcium tablets have not been established in pediatric populations.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.1"></a><p></p>
<p class="First"><span class="Underline">Amlodipine</span></p>
<p>Amlodipine (2.5 to 5 mg daily) is effective in lowering blood pressure in patients 6 to 17 years <span class="Italics">[see<a href="#S14.1"> Clinical Studies (14.1)</a>]</span>. The effect of amlodipine on blood pressure in patients less than 6 years of age is not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.2"></a><p></p>
<p class="First"><span class="Underline">Atorvastatin</span></p>
<p>Safety and effectiveness in patients 10–17 years of age with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> have been evaluated in a controlled clinical trial of 6 months' duration in adolescent boys and postmenarchal girls. Patients treated with atorvastatin had an adverse experience profile generally similar to that of patients treated with placebo. The most common adverse experiences observed in both groups, regardless of causality assessment, were <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Doses greater than 20 mg have not been studied in this patient population. In this limited controlled study, there was no significant effect on growth or sexual maturation in boys or on menstrual cycle length in girls <span class="Italics">[see<a href="#S14.11"> Clinical Studies (14.11)</a>,<a href="#S6.1"> Adverse Reactions (6.1)</a>, and<a href="#S2"> Dosage and Administration (2)</a>]</span>. Adolescent females should be counseled on appropriate contraceptive methods while on atorvastatin therapy <span class="Italics">[see<a href="#S4.2"> Contraindications (4.2) </a>and<a href="#S8.1"> Use in Specific Populations (8.1)</a>]</span>. Atorvastatin has not been studied in controlled clinical trials involving pre-pubertal patients or patients younger than 10 years of age.</p>
<p>Clinical efficacy with doses of atorvastatin up to 80 mg/day for 1 year have been evaluated in an uncontrolled study of patients with homozygous FH including 8 pediatric patients <span class="Italics">[see<a href="#S14.10"> Clinical Studies (14.10)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Safety and effectiveness of amlodipine besylate and atorvastatin calcium tablets have not been established in geriatric populations.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.1"></a><p></p>
<p class="First"><span class="Underline">Amlodipine</span></p>
<p>Clinical studies of amlodipine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Elderly patients have decreased clearance of amlodipine with a resulting increase of AUC of approximately 40–60%, and a lower initial dose may be required <span class="Italics">[see </span><span class="Italics"><a href="#S2">Dosage and Administration (2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.2"></a><p></p>
<p class="First"><span class="Underline">Atorvastatin</span></p>
<p>Of the 39,828 patients who received atorvastatin in clinical studies, 15,813 (40%) were ≥65 years old and 2,800 (7%) were ≥75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Advanced age (≥65 years) is a predisposing factor for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Amlodipine besylate and atorvastatin calcium tablets are contraindicated in patients with active liver disease which may include unexplained persistent elevations in hepatic transaminase levels <span class="Italics">[see<a href="#S4.1"> Contraindications (4.1) </a>and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">There is no information on overdosage with amlodipine besylate and atorvastatin calcium tablets in humans.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<p class="First"><span class="Underline">Amlodipine</span></p>
<p>Overdosage might be expected to cause excessive peripheral vasodilation with marked <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and possibly a <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span>. In humans, experience with intentional overdosage of amlodipine is limited.</p>
<p>Single oral doses of amlodipine maleate equivalent to 40 mg amlodipine/kg and 100 mg amlodipine/kg in mice and rats, respectively, caused <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Single oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg or higher in dogs (11 or more times the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) caused a marked peripheral vasodilation and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>If <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should occur with amlodipine, initiate active cardiac and respiratory monitoring. Perform frequent blood pressure measurements. Should <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occur, provide cardiovascular support including elevation of the extremities and administration of fluids. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> remains unresponsive to these conservative measures, consider administration of vasopressors (such as phenylephrine) with specific attention to circulating volume and urine output. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<p class="First"><span class="Underline">Atorvastatin</span></p>
<p>There is no specific treatment for atorvastatin overdosage. In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the patient should be treated symptomatically, and supportive measures instituted as required. Because of extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">Amlodipine besylate and atorvastatin calcium tablets combine the calcium channel blocker amlodipine besylate with the HMG CoA-reductase inhibitor atorvastatin calcium.</p>
<p>Amlodipine besylate is chemically described as 3-ethyl-5-methyl (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. Its empirical formula is C<span class="Bold"><span class="Sub">20</span></span>H<span class="Bold"><span class="Sub">25</span></span>ClN<span class="Bold"><span class="Sub">2</span></span>O<span class="Bold"><span class="Sub">5</span></span>•C<span class="Bold"><span class="Sub">6</span></span>H<span class="Bold"><span class="Sub">6</span></span>O<span class="Bold"><span class="Sub">3</span></span>S.</p>
<p>Atorvastatin calcium is chemically described as [R-(R*, R*)]-2-(4-fluorophenyl)-ß, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate. Its empirical formula is (C<span class="Sub">33</span>H<span class="Sub">34</span> FN<span class="Sub">2</span>O<span class="Sub">5</span>)<span class="Sub">2</span>Ca•3H<span class="Sub">2</span>O.</p>
<p>The structural formulae for amlodipine besylate and atorvastatin calcium are shown below.</p>
<table class="Noautorules" width="100%">
<col align="left" valign="bottom" width="30%">
<col align="left" valign="bottom" width="70%">
<tbody class="Headless">
<tr>
<td align="left"><p class="First"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-01.jpg"></p></td>
<td align="left"><p class="First"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-02.jpg"></p></td>
</tr>
<tr>
<td align="center">Amlodipine besylate</td>
<td align="left">            Atorvastatin calcium </td>
</tr>
</tbody>
</table>
<p>Amlodipine besylate and atorvastatin calcium tablet contains amlodipine besylate, a white to off-white crystalline powder, and atorvastatin calcium, also a white to off-white crystalline powder. Amlodipine besylate has a molecular weight of 567.1 and atorvastatin calcium has a molecular weight of 1209.42. Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol. Atorvastatin calcium is insoluble in aqueous solutions of pH 4 and below. Atorvastatin calcium is very slightly soluble in distilled water, pH 7.4 phosphate buffer, and acetonitrile; slightly soluble in ethanol; and freely soluble in methanol.</p>
<p>Each film-coated tablet also contains calcium carbonate, croscarmellose sodium, microcrystalline cellulose, pregelatinized starch, polysorbate 80, hydroxypropyl cellulose, purified water, colloidal silicon dioxide (anhydrous), magnesium stearate, Opadry® II White 85F28751 (polyvinyl alcohol, titanium dioxide, PEG 3000, and talc) or Opadry® II Blue 85F10919 (polyvinyl alcohol, titanium dioxide, PEG 3000, talc, and FD&amp;C blue #2).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12   CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Amlodipine besylate and atorvastatin calcium tablets are a combination of two drugs, a dihydropyridine calcium channel blocker (amlodipine) and an HMG-CoA reductase inhibitor (atorvastatin). The amlodipine component of amlodipine besylate and atorvastatin calcium tablets inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The atorvastatin component of amlodipine besylate and atorvastatin calcium tablets is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.1"></a><p></p>
<p class="First"><span class="Underline">Amlodipine</span></p>
<p>Amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected <span class="Italics">in vitro</span> but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine.</p>
<p>Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and reduction in blood pressure.</p>
<p>The precise mechanisms by which amlodipine relieves angina have not been fully delineated, but are thought to include the following:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Exertional Angina:</span> In patients with exertional angina, amlodipine reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Vasospastic Angina: </span>Amlodipine has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels <span class="Italics">in vitro</span>. This inhibition of coronary spasm is responsible for the effectiveness of amlodipine in vasospastic (Prinzmetal's or variant) angina.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.2"></a><p></p>
<p class="First"><span class="Underline">Atorvastatin</span></p>
<p><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> and triglycerides circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), IDL (intermediate-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides (TG) and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily through the high-affinity LDL receptor.</p>
<p>Clinical and pathologic studies show that elevated plasma levels of total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (total-C), LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C), and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B (<span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>) promote human <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> and are risk factors for developing cardiovascular disease, while increased levels of HDL-C are associated with a decreased cardiovascular risk.</p>
<p>Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C, and inversely with the level of HDL-C.</p>
<p>In animal models, atorvastatin lowers plasma <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and lipoprotein levels by inhibiting HMG-CoA reductase and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles.</p>
<p>Atorvastatin reduces total-C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span> in patients with homozygous and <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (FH), nonfamilial forms of <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. Atorvastatin also reduces VLDL-C and TG and produces variable increases in HDL-C and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> A-1. Atorvastatin reduces total-C, LDL-C, VLDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, TG, and non-HDL-C, and increases HDL-C in patients with isolated <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>. Atorvastatin reduces intermediate density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (IDL-C) in patients with dysbetalipoproteinemia.</p>
<p>Like LDL, <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-enriched triglyceride-rich lipoproteins, including VLDL, intermediate density lipoprotein (IDL), and remnants, can also promote <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. Elevated plasma triglycerides are frequently found in a triad with low HDL-C levels and small LDL particles, as well as in association with non-lipid metabolic risk factors for coronary heart disease. As such, total plasma TG has not consistently been shown to be an independent risk factor for CHD. Furthermore, the independent effect of raising HDL or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.</p>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2	  Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline">Amlodipine</span></p>
<p>Following administration of therapeutic doses to patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, amlodipine produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing. Although the acute intravenous administration of amlodipine decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral administration of amlodipine in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina.</p>
<p>With chronic once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours. Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with amlodipine is also correlated with the height of pretreatment elevation; thus, individuals with moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic pressure 105–114 mmHg) had about a 50% greater response than patients with mild <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic pressure 90–104 mmHg). Normotensive subjects experienced no clinically significant change in blood pressures (+1/–2 mmHg).</p>
<p>In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>.</p>
<p>As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In hemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and man, even when co-administered with beta-blockers to man. Similar findings, however, have been observed in normal or well-compensated patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with agents possessing significant negative inotropic effects.</p>
<p>Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man. In patients with chronic stable angina, intravenous administration of 10 mg did not significantly alter A-H and H-V conduction and sinus node recovery time after pacing. Similar results were obtained in patients receiving amlodipine and concomitant beta-blockers. In clinical studies in which amlodipine was administered in combination with beta-blockers to patients with either <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or angina, no adverse effects on electrocardiographic parameters were observed. In clinical trials with angina patients alone, amlodipine therapy did not alter electrocardiographic intervals or produce higher degrees of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV blocks</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Underline">Atorvastatin</span></p>
<p>Atorvastatin, as well as some of its metabolites, are pharmacologically active in humans. The liver is the primary site of action and the principal site of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and LDL clearance. Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response <span class="Italics">[see </span><span class="Italics"><a href="#S2">Dosage and Administration (2)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1.1"></a><p></p>
<p class="First"><span class="Italics">Amlodipine:</span> After oral administration of therapeutic doses of amlodipine alone, absorption produces peak plasma concentrations between 6 and 12 hours. Absolute bioavailability has been estimated to be between 64% and 90%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1.2"></a><p></p>
<p class="First"><span class="Italics">Atorvastatin: </span>After oral administration alone, atorvastatin is rapidly absorbed; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration <span class="Italics">[see<a href="#S2"> Dosage and Administration (2)</a>].</span></p>
<p>Amlodipine besylate and atorvastatin calcium tablets: Following oral administration of amlodipine besylate and atorvastatin calcium tablets, peak plasma concentrations of amlodipine and atorvastatin are seen at 6 to 12 hours and 1 to 2 hours post dosing, respectively. The rate and extent of absorption (bioavailability) of amlodipine and atorvastatin from amlodipine besylate and atorvastatin calcium tablets are not significantly different from the bioavailability of amlodipine and atorvastatin administered separately (see above).</p>
<p>The bioavailability of amlodipine from amlodipine besylate and atorvastatin calcium tablets was not affected by food. Food decreases the rate and extent of absorption of atorvastatin from amlodipine besylate and atorvastatin calcium tablets by approximately 32% and 11%, respectively, as it does with atorvastatin when given alone. LDL-C reduction is similar whether atorvastatin is given with or without food.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2.1"></a><p></p>
<p class="First"><span class="Italics">Amlodipine: </span><span class="Italics">Ex vivo</span> studies have shown that approximately 93% of the circulating amlodipine drug is bound to plasma proteins in hypertensive patients. Steady-state plasma levels of amlodipine are reached after 7 to 8 days of consecutive daily dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2.2"></a><p></p>
<p class="First"><span class="Italics">Atorvastatin:</span> Mean volume of distribution of atorvastatin is approximately 381 liters. Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, atorvastatin calcium is likely to be secreted in human milk <span class="Italics">[see<a href="#S4.3"> Contraindications (4.3) </a>and<a href="#S8.3"> Use in Specific Populations (8.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.1"></a><p></p>
<p class="First"><span class="Italics">Amlodipine:</span> Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.2"></a><p></p>
<p class="First"><span class="Italics">Atorvastatin:</span> Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. <span class="Italics">In vitro</span> inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.</p>
<p><span class="Italics">In vitro</span> studies suggest the importance of atorvastatin metabolism by cytochrome P4503A4, consistent with increased plasma concentrations of atorvastatin in humans following co-administration with erythromycin, a known inhibitor of this isozyme <span class="Italics">[see<a href="#S7.13"> Drug Interactions (7.13)</a>]</span>. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Excretion</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.1"></a><p></p>
<p class="First"><span class="Italics">Amlodipine:</span> Elimination from the plasma is biphasic with a terminal elimination half-life of about 30–50 hours. Ten percent of the parent amlodipine compound and 60% of the metabolites of amlodipine are excreted in the urine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.2"></a><p></p>
<p class="First"><span class="Italics">Atorvastatin:</span> Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours because of the contribution of active metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following oral administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Underline">Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Italics">Geriatric</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1.1"></a><p></p>
<p class="First"><span class="Italics">Amlodipine:</span> Elderly patients have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40–60%, and a lower initial dose of amlodipine may be required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1.2"></a><p></p>
<p class="First"><span class="Italics">Atorvastatin:</span> Plasma concentrations of atorvastatin are higher (approximately 40% for Cmax and 30% for AUC) in healthy elderly subjects (age ≥65 years) than in young adults. Clinical data suggest a greater degree of LDL-lowering at any dose of atorvastatin in the elderly population compared to younger adults <span class="Italics">[see<a href="#S8.5"> Use in Specific Populations (8.5)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Italics">Pediatric</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2.1"></a><p></p>
<p class="First"><span class="Italics">Amlodipine:</span> Sixty-two hypertensive patients aged 6 to 17 years received doses of amlodipine between 1.25 mg and 20 mg. Weight-adjusted clearance and volume of distribution were similar to values in adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2.2"></a><p></p>
<p class="First"><span class="Italics">Atorvastatin:</span> Pharmacokinetic data in the pediatric population are not available.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.3"></a><p></p>
<p class="First"><span class="Italics">Gender</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.3.1"></a><p></p>
<p class="First"><span class="Italics">Atorvastatin:</span> Plasma concentrations of atorvastatin in women differ from those in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with atorvastatin between men and women.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.4.1"></a><p></p>
<p class="First"><span class="Italics">Amlodipine:</span> The pharmacokinetics of amlodipine are not significantly influenced by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> may therefore receive the usual initial amlodipine dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.4.2"></a><p></p>
<p class="First"><span class="Italics">Atorvastatin:</span> <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal disease</span> has no influence on the plasma concentrations or LDL-C reduction of atorvastatin; thus, dose adjustment of atorvastatin in patients with renal dysfunction is not necessary <span class="Italics">[see<a href="#S2"> Dosage and Administration (2) </a>and<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.5"></a><p></p>
<p class="First"><span class="Italics">Hemodialysis</span></p>
<p>While studies have not been conducted in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, hemodialysis is not expected to clear atorvastatin or amlodipine since both drugs are extensively bound to plasma proteins.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.6"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.6.1"></a><p></p>
<p class="First"><span class="Italics">Amlodipine:</span> Elderly patients and patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40–60%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.6.2"></a><p></p>
<p class="First"><span class="Italics">Atorvastatin:</span> In patients with chronic <span class="product-label-link" type="condition" conceptid="201612" conceptname="Alcoholic liver damage">alcoholic liver disease</span>, plasma concentrations of atorvastatin are markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC of atorvastatin are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease <span class="Italics">[see<a href="#S4.1"> Contraindications (4.1)</a>]</span>.</p>
<p>Atorvastatin is contraindicated in patients with active liver disease.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.7"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.7.1"></a><p></p>
<p class="First"><span class="Italics">Amlodipine:</span> In patients with moderate to severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, the increase in AUC for amlodipine was similar to that seen in the elderly and in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Underline">Effects of Other Drugs on Amlodipine Besylate and Atorvastatin Calcium Tablets</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.1"></a><p></p>
<p class="First"><span class="Italics">Amlodipine: </span>No significant interactions are known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.2"></a><p></p>
<p class="First"><span class="Italics">Atorvastatin: </span>Table 5 shows effects of other drugs on the pharmacokinetics of atorvastatin.</p>
<table width="75%">
<caption><span>Table 5. Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin</span></caption>
<col align="left" valign="top" width="39%">
<col align="left" valign="top" width="32%">
<col align="left" valign="top" width="14%">
<col align="left" valign="top" width="15%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center">Co-administered drug and dosing regimen</th>
<th class="Rrule" align="center" colspan="3">Atorvastatin</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="left">Dose (mg)</th>
<th class="Rrule" align="left">Change  in AUC</th>
<th class="Rrule" align="left">Change in Cmax</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>See <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#S7">Drug Interactions (7)</a></span> for clinical significance.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, use the lowest dose necessary.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">‡</a></dt>
<dd>Greater increases in AUC (up to 2.5-fold) and/or Cmax (up to 71%) have been reported with excessive grapefruit consumption (≥ 750 mL – 1.2 liters per day).</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">§</a></dt>
<dd>Single sample taken 8–16 h post dose.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">¶</a></dt>
<dd>Because of the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">
<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>Cyclosporine 5.2 mg/kg/day, stable dose</td>
<td class="Rrule" align="left">10 mg QD for 28 days</td>
<td class="Rrule" align="left">↑ 870%</td>
<td class="Rrule" align="left">↑1070%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a>Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days</td>
<td class="Rrule" align="left">10 mg, SD</td>
<td class="Rrule" align="left">↑ 940%</td>
<td class="Rrule" align="left" valign="middle">↑ 860%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a>Telaprevir 750 mg q8h, 10 days</td>
<td class="Rrule" align="left">20 mg, SD</td>
<td class="Rrule" align="left">↑ 790%</td>
<td class="Rrule" align="left" valign="middle">↑ 1060%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>Saquinavir 400 mg BID/ritonavir 400mg BID, 15 days</td>
<td class="Rrule" align="left">40 mg QD for 4 days</td>
<td class="Rrule" align="left">↑ 390%</td>
<td class="Rrule" align="left">↑ 430%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a>Clarithromycin 500 mg BID, 9 days</td>
<td class="Rrule" align="left">80 mg QD for 8 days</td>
<td class="Rrule" align="left">↑ 440%</td>
<td class="Rrule" align="left">↑ 540%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a>Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days</td>
<td class="Rrule" align="left">10 mg QD for 4 days</td>
<td class="Rrule" align="left">↑ 340%</td>
<td class="Rrule" align="left" valign="middle">↑ 230%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a>Itraconazole 200 mg QD, 4 days</td>
<td class="Rrule" align="left">40 mg SD</td>
<td class="Rrule" align="left">↑ 330%</td>
<td class="Rrule" align="left">↑ 20% </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a>Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days</td>
<td class="Rrule" align="left">10 mg QD for 4 days</td>
<td class="Rrule" align="left">↑ 250%</td>
<td class="Rrule" align="left" valign="middle">↑ 280%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a>Fosamprenavir 1400 mg BID, 14 days</td>
<td class="Rrule" align="left">10 mg QD for 4 days</td>
<td class="Rrule" align="left">↑ 230%</td>
<td class="Rrule" align="left" valign="middle">↑ 400%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a>Nelfinavir 1250 mg BID, 14 days</td>
<td class="Rrule" align="left">10 mg QD for 28 days</td>
<td class="Rrule" align="left">↑ 74%</td>
<td class="Rrule" align="left" valign="middle">↑ 220%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a>Grapefruit Juice, 240 mL QD<a name="footnote-reference-9" href="#footnote-9" class="Sup">‡</a>
</td>
<td class="Rrule" align="left">40 mg, SD</td>
<td class="Rrule" align="left">↑ 37%</td>
<td class="Rrule" align="left">↑ 16%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Diltiazem 240 mg QD, 28 days</td>
<td class="Rrule" align="left">40 mg, SD</td>
<td class="Rrule" align="left">↑ 51%</td>
<td class="Rrule" align="left">No change</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Erythromycin 500 mg QID, 7 days</td>
<td class="Rrule" align="left">10 mg, SD</td>
<td class="Rrule" align="left">↑ 33%</td>
<td class="Rrule" align="left">↑ 38%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Amlodipine 10 mg, single dose</td>
<td class="Rrule" align="left">80 mg, SD</td>
<td class="Rrule" align="left">↑ 15%</td>
<td class="Rrule" align="left">↓ 12 %</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Cimetidine 300 mg QD, 4 weeks</td>
<td class="Rrule" align="left">10 mg QD for 2 weeks</td>
<td class="Rrule" align="left">↓ Less than 1%</td>
<td class="Rrule" align="left">↓ 11%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Colestipol 10 mg BID, 28 weeks</td>
<td class="Rrule" align="left">40 mg QD for 28 weeks</td>
<td class="Rrule" align="left">Not determined</td>
<td class="Rrule" align="left">↓ 26%<a name="footnote-reference-10" href="#footnote-10" class="Sup">§</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Maalox TC® 30 mL QD, 17 days</td>
<td class="Rrule" align="left">10 mg QD for 15 days</td>
<td class="Rrule" align="left">↓ 33%</td>
<td class="Rrule" align="left">↓ 34%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Efavirenz 600 mg QD, 14 days</td>
<td class="Rrule" align="left">10 mg for 3 days</td>
<td class="Rrule" align="left">↓ 41%</td>
<td class="Rrule" align="left">↓ 1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a>Rifampin 600 mg QD, 7 days (co-administered) <a name="footnote-reference-11" href="#footnote-11" class="Sup">¶</a>
</td>
<td class="Rrule" align="left">40 mg SD</td>
<td class="Rrule" align="left">↑ 30%</td>
<td class="Rrule" align="left">↑ 2.7-fold</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a>Rifampin 600 mg QD, 5 days (doses separated) <a href="#footnote-11" class="Sup">¶</a>
</td>
<td class="Rrule" align="left">40 mg SD</td>
<td class="Rrule" align="left">↓ 80%</td>
<td class="Rrule" align="left">↓ 40%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a>Gemfibrozil 600 mg BID, 7 days</td>
<td class="Rrule" align="left">40mg SD </td>
<td class="Rrule" align="left">↑ 35%</td>
<td class="Rrule" align="left">↓ Less than 1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<a href="#footnote-7" class="Sup">*</a>Fenofibrate 160 mg QD, 7 days</td>
<td class="Rrule" align="left">40mg SD      </td>
<td class="Rrule" align="left">↑ 3%</td>
<td class="Rrule" align="left">↑ 2%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Boceprevir 800 mg TID, 7 days</td>
<td class="Rrule" align="left">40 mg SD</td>
<td class="Rrule" align="left">↑2.30 fold</td>
<td class="Rrule" align="left">↑2.66 fold</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Underline">Effects of Amlodipine Besylate and Atorvastatin Calcium Tablets on Other Drugs</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.1"></a><p></p>
<p class="First"><span class="Italics">Amlodipine: </span>No significant interactions are known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.2"></a><p></p>
<p class="First"><span class="Italics">Atorvastatin: </span>Table 6 shows the effects of atorvastatin on the pharmacokinetics of other drugs.</p>
<table width="75%">
<caption><span>Table 6. Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs</span></caption>
<col align="left" valign="middle" width="25%">
<col align="left" valign="middle" width="30%">
<col align="left" valign="middle" width="22%">
<col align="left" valign="middle" width="23%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center">Atorvastatin</th>
<th class="Rrule" align="center" colspan="3">Co-administered drug and dosing regimen</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="left">Drug/Dose (mg)</th>
<th class="Rrule" align="left">Change in AUC</th>
<th class="Rrule" align="left">Change in Cmax</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">80 mg QD for 15 days</td>
<td class="Rrule" align="left">Antipyrine, 600 mg SD</td>
<td class="Rrule" align="left">↑ 3%</td>
<td class="Rrule" align="left">↓ 11%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">80 mg QD for 14 days</td>
<td class="Rrule" align="left">Digoxin 0.25 mg QD, 20 days</td>
<td class="Rrule" align="left">↑ 15%</td>
<td class="Rrule" align="left">↑ 20 %</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">40 mg QD for 22 days</td>
<td class="Rrule" align="left">Oral contraceptive QD, 2 months</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left">– norethindrone 1mg</td>
<td class="Rrule" align="left">↑ 28%</td>
<td class="Rrule" align="left">↑ 23%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left">– ethinyl estradiol 35 µg</td>
<td class="Rrule" align="left">↑ 19%</td>
<td class="Rrule" align="left">↑ 30%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">10 mg, SD</td>
<td class="Rrule" align="left">Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days</td>
<td class="Rrule" align="left">No change</td>
<td class="Rrule" align="left">No change</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">10 mg QD for 4 days</td>
<td class="Rrule" align="left">Fosamprenavir 1400 mg BID, 14 days</td>
<td class="Rrule" align="left">↓ 27%</td>
<td class="Rrule" align="left">↓ 18%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">10 mg QD for 4 days</td>
<td class="Rrule" align="left">Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days</td>
<td class="Rrule" align="left">No change</td>
<td class="Rrule" align="left">No change</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Underline">Amlodipine</span></p>
<p>Rats and mice treated with amlodipine maleate in the diet for up to two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg amlodipine/kg/day, showed no evidence of a carcinogenic effect of the drug. For the mouse, the highest dose was, on a mg/m<span class="Sup">2</span> basis, similar to the maximum recommended human dose of 10 mg amlodipine/day.<a name="footnote-reference-12" href="#footnote-12" class="Sup">3</a> For the rat, the highest dose level was, on a mg/m<span class="Sup">2</span> basis, about twice the maximum recommended human dose. <a href="#footnote-12" class="Sup">3</a></p>
<p>Mutagenicity studies conducted with amlodipine maleate revealed no drug related effects at either the gene or chromosome levels.</p>
<p>There was no effect on the fertility of rats treated orally with amlodipine maleate (males for 64 days and females for 14 days prior to mating) at doses up to 10 mg amlodipine/kg/day (8 times the maximum recommended human dose <a href="#footnote-12" class="Sup">3</a> of 10 mg/day on a mg/m<span class="Sup">2</span> basis).</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">3</a></dt>
<dd>Based on patient weight of 50 kg.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Underline">Atorvastatin</span></p>
<p>In a 2-year carcinogenicity study with atorvastatin calcium in rats at dose levels equivalent to 10, 30, and 100 mg atorvastatin/kg/day, 2 rare tumors were found in muscle in high-dose females: in one, there was a <span class="product-label-link" type="condition" conceptid="4116201" conceptname="Rhabdomyosarcoma">rhabdomyosarcoma</span> and, in another, there was a <span class="product-label-link" type="condition" conceptid="4202374" conceptname="Fibrosarcoma">fibrosarcoma</span>. This dose represents a plasma AUC (0–24) value of approximately 16 times the mean human plasma drug exposure after an 80 mg oral dose.</p>
<p>A 2-year carcinogenicity study in mice given atorvastatin calcium at dose levels equivalent to 100, 200, or 400 mg atorvastatin/kg/day resulted in a significant increase in liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in high-dose males and <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">liver carcinomas</span> in high-dose females. These findings occurred at plasma AUC (0–24) values of approximately 6 times the mean human plasma drug exposure after an 80 mg oral dose.</p>
<p><span class="Italics">In vitro,</span> atorvastatin was not mutagenic or clastogenic in the following tests with and without metabolic activation: the Ames test with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> and <span class="Italics">Escherichia coli,</span> the HGPRT forward mutation assay in Chinese hamster lung cells, and the chromosomal aberration assay in Chinese hamster lung cells. Atorvastatin was negative in the <span class="Italics">in vivo </span>mouse micronucleus test.</p>
<p>There were no effects on fertility when rats were given atorvastatin calcium at doses equivalent to up to 175 mg atorvastatin/kg/day (15 times the human exposure). There was <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> and <span class="product-label-link" type="condition" conceptid="40492473" conceptname="Aspermia">aspermia</span> in the epididymides of 2 of 10 rats treated with atorvastatin calcium at a dose equivalent to 100 mg atorvastatin/kg/day for 3 months (16 times the human AUC at the 80 mg dose); testis weights were significantly lower at 30 and 100 mg/kg/day and epididymal weight was lower at 100 mg/kg/day. Male rats given the equivalent of 100 mg atorvastatin/kg/day for 11 weeks prior to mating had decreased sperm motility, spermatid head concentration, and increased abnormal sperm. Atorvastatin caused no adverse effects on semen parameters, or reproductive organ histopathology in dogs given doses of atorvastatin calcium equivalent to 10, 40, or 120 mg atorvastatin/kg/day for two years.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Amlodipine for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Underline">Adult Patients</span></p>
<p>The antihypertensive efficacy of amlodipine has been demonstrated in a total of 15 double-blind, placebo-controlled, randomized studies involving 800 patients on amlodipine and 538 on placebo. Once daily administration produced statistically significant placebo-corrected reductions in supine and standing blood pressures at 24 hours postdose, averaging about 12/6 mmHg in the standing position and 13/7 mmHg in the supine position in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Maintenance of the blood pressure effect over the 24-hour dosing interval was observed, with little difference in peak and trough effect. Tolerance was not demonstrated in patients studied for up to 1 year. The 3 parallel, fixed dose, dose response studies showed that the reduction in supine and standing blood pressures was dose related within the recommended dosing range. Effects on diastolic pressure were similar in young and older patients. The effect on systolic pressure was greater in older patients, perhaps because of greater baseline systolic pressure. Effects were similar in black patients and in white patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Underline">Pediatric Patients</span></p>
<p>Two hundred sixty-eight hypertensive patients aged 6 to 17 years were randomized first to amlodipine 2.5 or 5 mg once daily for 4 weeks and then randomized again to the same dose or to placebo for another 4 weeks. Patients receiving 2.5 mg or 5 mg at the end of 8 weeks had significantly lower systolic blood pressure than those secondarily randomized to placebo. The magnitude of the treatment effect is difficult to interpret, but it is probably less than 5 mmHg systolic on the 5 mg dose and 3.3 mmHg systolic on the 2.5 mg dose. Adverse events were similar to those seen in adults.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2	Amlodipine for Chronic Stable Angina</h2>
<p class="First">The effectiveness of 5–10 mg/day of amlodipine in exercise-induced angina has been evaluated in 8 placebo-controlled, double-blind clinical trials of up to 6 weeks duration involving 1038 patients (684 amlodipine, 354 placebo) with chronic stable angina. In 5 of the 8 studies, significant increases in exercise time (bicycle or treadmill) were seen with the 10 mg dose. Increases in symptom-limited exercise time averaged 12.8% (63 sec) for amlodipine 10 mg, and averaged 7.9% (38 sec) for amlodipine 5 mg. Amlodipine 10 mg also increased time to 1 mm ST segment deviation in several studies and decreased <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina attack</span> rate. The sustained efficacy of amlodipine in angina patients has been demonstrated over long-term dosing. In patients with angina, there were no clinically significant reductions in blood pressures (4/1 mmHg) or changes in heart rate (+0.3 bpm).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3	Amlodipine for Vasospastic Angina</h2>
<p class="First">In a double-blind, placebo-controlled clinical trial of 4 weeks duration in 50 patients, amlodipine therapy decreased attacks by approximately 4/week compared with a placebo decrease of approximately 1/week (p&lt;0.01). Two of 23 amlodipine and 7 of 27 placebo patients discontinued from the study for lack of clinical improvement.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.4"></a><a name="section-13.4"></a><p></p>
<h2>14.4	Amlodipine for <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span></h2>
<p class="First">In PREVENT, 825 patients with angiographically documented <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> were randomized to amlodipine (5–10 mg once daily) or placebo and followed for 3 years. Although the study did not show significance on the primary objective of change in coronary luminal diameter as assessed by quantitative coronary angiography, the data suggested a favorable outcome with respect to fewer hospitalizations for angina and revascularization procedures in patients with CAD.</p>
<p>CAMELOT enrolled 1318 patients with CAD recently documented by angiography, without left main <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary disease</span> and without <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or an <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> &lt;40%. Patients (76% males, 89% Caucasian, 93% enrolled at U.S. sites, 89% with a history of angina, 52% without PCI, 4% with PCI and no stent, and 44% with a stent) were randomized to double-blind treatment with either amlodipine (5–10 mg once daily) or placebo in addition to standard care that included aspirin (89%), statins (83%), beta-blockers (74%), nitroglycerin (50%), anticoagulants (40%), and diuretics (32%), but excluded other calcium channel blockers. The mean duration of follow-up was 19 months. The primary endpoint was the time to first occurrence of one of the following events: hospitalization for <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, coronary revascularization, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>/TIA, or <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>. A total of 110 (16.6%) and 151 (23.1%) first events occurred in the amlodipine and placebo groups, respectively, for a hazard ratio of 0.691 (95% CI: 0.540–0.884, p = 0.003). The primary endpoint is summarized in Figure 1 below. The outcome of this study was largely derived from the prevention of hospitalizations for angina and the prevention of revascularization procedures (see<a href="#table7"> Table 7</a>). Effects in various subgroups are shown in Figure 2.</p>
<p>In an angiographic substudy (n=274) conducted within CAMELOT, there was no significant difference between amlodipine and placebo on the change of atheroma volume in the coronary artery as assessed by intravascular ultrasound.</p>
<p><span class="Bold">Figure 1. Kaplan-Meier Analysis of Composite Clinical Outcomes for Amlodipine versus Placebo</span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-03.jpg"></div>
<p><span class="Bold">Figure 2. Effects on Primary Endpoint of Amlodipine versus Placebo across Sub-Groups</span></p>
<p><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-04.jpg"></p>
<p>Table 7 below summarizes the significant composite endpoint and clinical outcomes from the composites of the primary endpoint. The other components of the primary endpoint including cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>/TIA, or <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> did not demonstrate a significant difference between amlodipine and placebo.</p>
<a name="table7"></a><table width="65%">
<caption><span>Table 7. Incidence of Significant Clinical Outcomes for CAMELOT</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th align="left">Clinical Outcomes<br>N (%)</th>
<th align="center">amlodipine<br>(N=663)</th>
<th align="center">Placebo<br>(N=655)</th>
<th align="center">Risk Reduction<br>(p-value)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>Total patients with these events.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Bold">Composite CV Endpoint</span></td>
<td align="center"><span class="Bold">110<br>(16.6)</span></td>
<td align="center">
<span class="Bold">151 </span><br><span class="Bold">(23.1)</span>
</td>
<td align="center">
<span class="Bold">31%</span><br><span class="Bold">(0.003)</span><br>
</td>
</tr>
<tr>
<td align="left">Hospitalization for Angina<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a>
</td>
<td align="center">51<br>(7.7)</td>
<td align="center">84<br>(12.8)</td>
<td align="center">42%<br>(0.002)<br>
</td>
</tr>
<tr class="Last">
<td align="left">Coronary Revascularization<a href="#footnote-13" class="Sup">*</a>
</td>
<td align="center">78<br> (11.8)</td>
<td align="center">103<br> (15.7)</td>
<td align="center">27%<br>(0.033)<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.5"></a><a name="section-13.5"></a><p></p>
<h2>14.5	Amlodipine for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h2>
<p class="First">Amlodipine has been compared to placebo in four 8–12 week studies of patients with NYHA Class II/III <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, involving a total of 697 patients. In these studies, there was no evidence of worsened <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> based on measures of exercise tolerance, NYHA classification, symptoms, or left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span>. In a long-term (follow-up at least 6 months, mean 13.8 months) placebo-controlled mortality/morbidity study of amlodipine 5–10 mg in 1153 patients with NYHA Classes III (n=931) or IV (n=222) <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> on stable doses of diuretics, digoxin, and ACE inhibitors, amlodipine had no effect on the primary endpoint of the study which was the combined endpoint of all-cause mortality and cardiac morbidity (as defined by life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, or hospitalization for worsened <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>), or on NYHA classification, or symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Total combined all-cause mortality and cardiac morbidity events were 222/571 (39%) for patients on amlodipine and 246/583 (42%) for patients on placebo; the cardiac morbid events represented about 25% of the endpoints in the study.</p>
<p>Another study (PRAISE-2) randomized patients with NYHA Class III (80%) or IV (20%) <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> without clinical symptoms or objective evidence of underlying ischemic disease, on stable doses of ACE inhibitors (99%), digitalis (99%), and diuretics (99%), to placebo (n=827) or amlodipine (n=827) and followed them for a mean of 33 months. There was no statistically significant difference between amlodipine and placebo in the primary endpoint of all-cause mortality (95% confidence limits from 8% reduction to 29% increase on amlodipine). With amlodipine there were more reports of <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.6"></a><a name="section-13.6"></a><p></p>
<h2>14.6	Atorvastatin for Prevention of Cardiovascular Disease</h2>
<p class="First">In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the effect of atorvastatin on fatal and non-fatal coronary heart disease was assessed in 10,305 hypertensive patients 40–80 years of age (mean of 63 years), without a previous <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and with TC levels ≤251 mg/dL (6.5 mmol/L). Additionally, all patients had at least 3 of the following cardiovascular risk factors: male gender (81.1%), age &gt;55 years (84.5%), smoking (33.2%), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (24.3%), history of CHD in a first-degree relative (26%), TC:HDL &gt;6 (14.3%), <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> (5.1%), <span class="product-label-link" type="condition" conceptid="4184746" conceptname="Left ventricular hypertrophy">left ventricular hypertrophy</span> (14.4%), prior cerebrovascular event (9.8%), specific ECG abnormality (14.3%), <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>/<span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span> (62.4%). In this double-blind, placebo-controlled study, patients were treated with anti-hypertensive therapy (Goal BP &lt;140/90 mmHg for non-diabetic patients; &lt;130/80 mm Hg for diabetic patients) and allocated to either atorvastatin 10 mg daily (n=5168) or placebo (n=5137), using a covariate adaptive method that took into account the distribution of nine baseline characteristics of patients already enrolled and minimized the imbalance of those characteristics across the groups. Patients were followed for a median duration of 3.3 years.</p>
<p>The effect of 10 mg/day of atorvastatin on lipid levels was similar to that seen in previous clinical trials.</p>
<p>Atorvastatin significantly reduced the rate of coronary events [either fatal coronary heart disease (46 events in the placebo group vs. 40 events in the atorvastatin group) or non-fatal MI (108 events in the placebo group vs. 60 events in the atorvastatin group)] with a relative risk reduction of 36% [(based on incidences of 1.9% for atorvastatin vs. 3.0% for placebo), p=0.0005 (see<a href="#fig3"> Figure 3</a>)]. The risk reduction was consistent regardless of age, smoking status, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, or presence of renal dysfunction. The effect of atorvastatin was seen regardless of baseline LDL levels. Because of the small number of events, results for women were inconclusive.</p>
<p><a name="fig3"></a><span class="Bold">Figure 3. Effect of Atorvastatin 10 mg/day on Cumulative Incidence of Non-Fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span> or Coronary Heart Disease <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (in ASCOT-LLA)</span></p>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-05.jpg"></div>
<p>Atorvastatin also significantly decreased the relative risk for revascularization procedures by 42%. Although the reduction of fatal and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> did not reach a pre-defined significance level (p=0.01), a favorable trend was observed with a 26% relative risk reduction (incidences of 1.7% for atorvastatin and 2.3% for placebo). There was no significant difference between the treatment groups for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from cardiovascular causes (p=0.51) or noncardiovascular causes (p=0.17).</p>
<p>In the Collaborative Atorvastatin <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Study (CARDS), the effect of atorvastatin on cardiovascular disease (CVD) endpoints was assessed in 2838 subjects (94% white, 68% male), ages 40–75 with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> based on WHO criteria, without prior history of cardiovascular disease, and with LDL ≤ 160 mg/dL and TG ≤ 600 mg/dL. In addition to <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, subjects had 1 or more of the following risk factors: current smoking (23%), <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (80%), <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> (30%), or <span class="product-label-link" type="condition" conceptid="4195061" conceptname="Microalbuminuria">microalbuminuria</span> (9%) or macroalbuminuria (3%). No subjects on hemodialysis were enrolled in the study. In this multicenter, placebo-controlled, double-blind clinical trial, subjects were randomly allocated to either atorvastatin 10 mg daily (1,429) or placebo (1,411) in a 1:1 ratio and were followed for a median duration of 3.9 years. The primary endpoint was the occurrence of any of the major cardiovascular events: <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, acute CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>, coronary revascularization, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. The primary analysis was the time to first occurrence of the primary endpoint.</p>
<p>Baseline characteristics of subjects were: mean age of 62 years; mean HbA<span class="Sub">1c</span> 7.7%; median LDL-C 120 mg/dL; median TC 207   mg/dL; median TG 151 mg/dL; median HDL-C 52 mg/dL.</p>
<p>The effect of atorvastatin 10 mg/day on lipid levels was similar to that seen in previous clinical trials.</p>
<p>Atorvastatin significantly reduced the rate of major cardiovascular events (primary endpoint events) (83 events in the atorvastatin group vs. 127 events in the placebo group) with a relative risk reduction of 37%, HR 0.63, 95% CI (0.48, 0.83) (p=0.001) (see<a href="#fig4"> Figure 4</a>). An effect of atorvastatin was seen regardless of age, sex, or baseline lipid levels.</p>
<p>Atorvastatin significantly reduced the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> by 48% (21 events in the atorvastatin group vs. 39 events in the placebo group), HR 0.52, 95% CI (0.31, 0.89) (p=0.016) and reduced the risk of MI by 42% (38 events in the atorvastatin group vs. 64 events in the placebo group), HR 0.58, 95.1% CI (0.39, 0.86) (p=0.007). There was no significant difference between the treatment groups for angina, revascularization procedures, and acute CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>There were 61 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the atorvastatin group vs. 82 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the placebo group (HR 0.73, p=0.059).</p>
<p><a name="fig4"></a><span class="Bold">Figure 4. Effect of Atorvastatin 10 mg/day on Time to Occurrence of Major Cardiovascular Events (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, acute CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>, coronary revascularization, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>) in CARDS</span></p>
<div class="Figure"><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-06.jpg"></div>
<p>In the Treating to New Targets Study (TNT), the effect of atorvastatin 80 mg/day vs. atorvastatin 10 mg/day on the reduction in cardiovascular events was assessed in 10,001 subjects (94% white, 81% male, 38% ≥65 years) with clinically evident coronary heart disease who had achieved a target LDL-C level &lt;130 mg/dL after completing an 8-week, open-label, run-in period with atorvastatin 10 mg/day. Subjects were randomly assigned to either 10 mg/day or 80 mg/day of atorvastatin and followed for a median duration of 4.9 years. The primary endpoint was the time to first occurrence of any of the following major cardiovascular events (MCVE): <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from CHD, non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and fatal and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. The mean LDL-C, TC, TG, non-HDL, and HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels at 12 weeks were 73, 145, 128, 98, and 47 mg/dL during treatment with 80 mg of atorvastatin and 99, 177, 152, 129, and 48 mg/dL during treatment with 10 mg of atorvastatin.</p>
<p>Treatment with atorvastatin 80 mg/day significantly reduced the rate of MCVE (434 events in the 80 mg/day group vs. 548 events in the 10 mg/day group) with a relative risk reduction of 22%, HR 0.78, 95% CI (0.69, 0.89), p=0.0002 (see<a href="#fig5"> Figure 5 </a>and<a href="#table8"> Table 8</a>). The overall risk reduction was consistent regardless of age (&lt;65, ≥65) or gender.</p>
<p><a name="fig5"></a><span class="Bold">Figure 5. Effect of Atorvastatin 80 mg/day vs. 10 mg/day on Time to Occurrence of Major Cardiovascular Events (TNT)</span></p>
<div class="Figure"><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-07.jpg"></div>
<a name="table8"></a><table width="75%">
<caption><span>Table 8. Overview of Efficacy Results in TNT</span></caption>
<col align="left" valign="top" width="38%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="22%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Endpoint</th>
<th class="Rrule" align="center" colspan="2">Atorvastatin<br>10 mg<br>(N=5006)</th>
<th class="Rrule" align="center" colspan="2">Atorvastatin<br>80 mg<br>(N=4995)</th>
<th class="Rrule" align="center" valign="middle">HR<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a> (95% CI)</th>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="6">HR=hazard ratio; CHD=coronary heart disease; CI=confidence interval; MI=<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; CHF=<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>; CV=cardiovascular; PVD=<span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>; CABG=coronary artery bypass graft</td></tr>
<tr class="Last"><td align="left" colspan="6">Confidence intervals for the Secondary Endpoints were not adjusted for multiple comparisons.</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>Atorvastatin 80 mg: atorvastatin 10 mg</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">†</a></dt>
<dd>Secondary endpoints not included in primary endpoint</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">‡</a></dt>
<dd>Component of other secondary endpoints</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">PRIMARY ENDPOINT</span></td>
<td class="Rrule" align="center">n</td>
<td class="Rrule" align="center">(%)</td>
<td class="Rrule" align="center">n</td>
<td class="Rrule" align="center">(%)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">First major cardiovascular endpoint</td>
<td class="Rrule" align="center">548</td>
<td class="Rrule" align="center">(10.9)</td>
<td class="Rrule" align="center">434</td>
<td class="Rrule" align="center">(8.7)</td>
<td class="Rrule" align="center">0.78 (0.69, 0.89)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Components of the Primary Endpoint</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></td>
<td class="Rrule" align="center">127</td>
<td class="Rrule" align="center">(2.5)</td>
<td class="Rrule" align="center">101</td>
<td class="Rrule" align="center">(2.0)</td>
<td class="Rrule" align="center">0.80 (0.61, 1.03)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Non-fatal, non-procedure related MI</td>
<td class="Rrule" align="center">308</td>
<td class="Rrule" align="center">(6.2)</td>
<td class="Rrule" align="center">243</td>
<td class="Rrule" align="center">(4.9)</td>
<td class="Rrule" align="center">0.78 (0.66, 0.93)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span></td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">(0.5)</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">(0.5)</td>
<td class="Rrule" align="center">0.96 (0.56, 1.67)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> (fatal and non-fatal)</td>
<td class="Rrule" align="center">155</td>
<td class="Rrule" align="center">(3.1)</td>
<td class="Rrule" align="center">117</td>
<td class="Rrule" align="center">(2.3)</td>
<td class="Rrule" align="center">0.75 (0.59, 0.96)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">SECONDARY ENDPOINTS<a name="footnote-reference-15" href="#footnote-15" class="Sup">†</a></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">First CHF with hospitalization</td>
<td class="Rrule" align="center">164</td>
<td class="Rrule" align="center">(3.3)</td>
<td class="Rrule" align="center">122</td>
<td class="Rrule" align="center">(2.4)</td>
<td class="Rrule" align="center">0.74 (0.59, 0.94)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">First PVD endpoint</td>
<td class="Rrule" align="center">282</td>
<td class="Rrule" align="center">(5.6)</td>
<td class="Rrule" align="center">275</td>
<td class="Rrule" align="center">(5.5)</td>
<td class="Rrule" align="center">0.97 (0.83, 1.15)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">First CABG or other coronary revascularization procedure<a name="footnote-reference-16" href="#footnote-16" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">904</td>
<td class="Rrule" align="center">(18.1)</td>
<td class="Rrule" align="center">667</td>
<td class="Rrule" align="center">(13.4)</td>
<td class="Rrule" align="center">0.72 (0.65, 0.80)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">First documented angina endpoint<a href="#footnote-16" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">615</td>
<td class="Rrule" align="center">(12.3)</td>
<td class="Rrule" align="center">545</td>
<td class="Rrule" align="center">(10.9)</td>
<td class="Rrule" align="center">0.88 (0.79, 0.99)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">All-cause mortality</td>
<td class="Rrule" align="center">282</td>
<td class="Rrule" align="center">(5.6)</td>
<td class="Rrule" align="center">284</td>
<td class="Rrule" align="center">(5.7)</td>
<td class="Rrule" align="center">1.01 (0.85, 1.19)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Components of All-Cause Mortality</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></td>
<td class="Rrule" align="center">155</td>
<td class="Rrule" align="center">(3.1)</td>
<td class="Rrule" align="center">126</td>
<td class="Rrule" align="center">(2.5)</td>
<td class="Rrule" align="center">0.81 (0.64, 1.03)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Noncardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></td>
<td class="Rrule" align="center">127</td>
<td class="Rrule" align="center">(2.5)</td>
<td class="Rrule" align="center">158</td>
<td class="Rrule" align="center">(3.2)</td>
<td class="Rrule" align="center">1.25 (0.99, 1.57)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Cancer <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></td>
<td class="Rrule" align="center">75</td>
<td class="Rrule" align="center">(1.5)</td>
<td class="Rrule" align="center">85</td>
<td class="Rrule" align="center">(1.7)</td>
<td class="Rrule" align="center">1.13 (0.83, 1.55)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Other non-CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></td>
<td class="Rrule" align="center">43</td>
<td class="Rrule" align="center">(0.9)</td>
<td class="Rrule" align="center">58</td>
<td class="Rrule" align="center">(1.2)</td>
<td class="Rrule" align="center">1.35 (0.91, 2.00)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>, homicide, and other traumatic non-CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">(0.2)</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">(0.3)</td>
<td class="Rrule" align="center">1.67 (0.73, 3.82)</td>
</tr>
</tbody>
</table>
<p>Of the events that comprised the primary efficacy endpoint, treatment with atorvastatin 80 mg/day significantly reduced the rate of non-fatal, non-procedure related MI and fatal and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, but not CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> (Table 8). Of the predefined secondary endpoints, treatment with atorvastatin 80 mg/day significantly reduced the rate of coronary revascularization, angina, and hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, but not <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>. The reduction in the rate of CHF with hospitalization was only observed in the 8% of patients with a prior history of CHF.</p>
<p>There was no significant difference between the treatment groups for all-cause mortality (Table 8). The proportions of subjects who experienced cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, including the components of CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, were numerically smaller in the atorvastatin 80 mg group than in the atorvastatin 10 mg treatment group. The proportions of subjects who experienced noncardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were numerically larger in the atorvastatin 80 mg group than in the atorvastatin 10 mg treatment group.</p>
<p>In the Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study (IDEAL), treatment with atorvastatin 80 mg/day was compared to treatment with simvastatin 20–40 mg/day in 8,888 subjects up to 80 years of age with a history of CHD to assess whether reduction in CV risk could be achieved. Patients were mainly male (81%), white (99%) with an average age of 61.7 years, and an average LDL-C of 121.5 mg/dL at randomization; 76% were on statin therapy. In this prospective, randomized, open-label, blinded endpoint (PROBE) trial with no run-in period, subjects were followed for a median duration of 4.8 years. The mean LDL-C, TC, TG, HDL, and non-HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels at Week 12 were 78, 145, 115, 45, and 100 mg/dL during treatment with 80 mg of atorvastatin and 105, 179, 142, 47, and 132 mg/dL during treatment with 20–40 mg of simvastatin.</p>
<p>There was no significant difference between the treatment groups for the primary endpoint, the rate of first major coronary event (fatal CHD, non-fatal MI, and resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>): 411 (9.3%) in the atorvastatin 80 mg/day group vs. 463 (10.4%) in the simvastatin 20–40 mg/day group, HR 0.89, 95% CI ( 0.78, 1.01), p=0.07.</p>
<p>There were no significant differences between the treatment groups for all-cause mortality: 366 (8.2%) in the atorvastatin 80 mg/day group vs. 374 (8.4%) in the simvastatin 20–40 mg/day group. The proportions of subjects who experienced CV or non-CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were similar for the atorvastatin 80 mg group and the simvastatin 20–40 mg group.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.7"></a><a name="section-13.7"></a><p></p>
<h2>14.7 Atorvastatin for <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> <span class="Italics">(Fredrickson</span> Types IIa and IIb)</h2>
<p class="First">Atorvastatin reduces total-C, LDL-C, VLDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, and TG, and increases HDL-C in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. Therapeutic response is seen within 2 weeks, and maximum response is usually achieved within 4 weeks and maintained during chronic therapy.</p>
<p>Atorvastatin is effective in a wide variety of patient populations with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, with and without <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, in men and women, and in the elderly.</p>
<p>In two multicenter, placebo-controlled, dose-response studies in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, atorvastatin given as a single dose over 6 weeks significantly reduced total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, and TG. (Pooled results are provided in Table 9.)</p>
<table width="85%">
<caption><span>Table 9. Dose Response in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Adjusted Mean % Change From Baseline)<a name="footnote-reference-17" href="#footnote-17" class="Sup">*</a></span></caption>
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<thead><tr class="First Last">
<th align="center">Dose</th>
<th align="center">N</th>
<th align="center">TC</th>
<th align="center">LDL-C</th>
<th align="center"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></th>
<th align="center">TG</th>
<th align="center">HDL-C</th>
<th align="center">Non-HDL-C/HDL-C</th>
</tr></thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-17" href="#footnote-reference-17">*</a></dt>
<dd>Results are pooled from 2 dose-response studies.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center">Placebo</td>
<td align="center">21</td>
<td align="center">4</td>
<td align="center">4</td>
<td align="center">3</td>
<td align="center">10</td>
<td align="center">-3</td>
<td align="center">7</td>
</tr>
<tr>
<td align="center">10</td>
<td align="center">22</td>
<td align="center">-29</td>
<td align="center">-39</td>
<td align="center">-32</td>
<td align="center">-19</td>
<td align="center">6</td>
<td align="center">-34</td>
</tr>
<tr>
<td align="center">20</td>
<td align="center">20</td>
<td align="center">-33</td>
<td align="center">-43</td>
<td align="center">-35</td>
<td align="center">-26</td>
<td align="center">9</td>
<td align="center">-41</td>
</tr>
<tr>
<td align="center">40</td>
<td align="center">21</td>
<td align="center">-37</td>
<td align="center">-50</td>
<td align="center">-42</td>
<td align="center">-29</td>
<td align="center">6</td>
<td align="center">-45</td>
</tr>
<tr class="Last">
<td align="center">80</td>
<td align="center">23</td>
<td align="center">-45</td>
<td align="center">-60</td>
<td align="center">-50</td>
<td align="center">-37</td>
<td align="center">5</td>
<td align="center">-53</td>
</tr>
</tbody>
</table>
<p>In patients with <span class="Italics">Fredrickson </span>Types IIa and IIb <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipoproteinemia</span> pooled from 24 controlled trials, the median (25<span class="Sup">th</span> and 75<span class="Sup">th</span> percentile) percent changes from baseline in HDL-C for atorvastatin 10, 20, 40, and 80 mg were 6.4 (-1.4, 14), 8.7 (0, 17), 7.8 (0, 16), and 5.1 (-2.7, 15), respectively. Additionally, analysis of the pooled data demonstrated consistent and significant decreases in total-C, LDL-C, TG, total-C/HDL-C, and LDL-C/HDL-C.</p>
<p>In three multicenter, double-blind studies in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, atorvastatin was compared to other statins. After randomization, patients were treated for 16 weeks with either atorvastatin 10 mg per day or a fixed dose of the comparative agent (Table 10).</p>
<table width="85%">
<caption><span>Table 10. Mean Percentage Change from Baseline at Endpoint (Double-Blind, Randomized, Active-Controlled Trials)</span></caption>
<col align="left" valign="bottom" width="17%">
<col align="center" valign="bottom" width="11%">
<col align="center" valign="bottom" width="12%">
<col align="center" valign="bottom" width="11%">
<col align="center" valign="bottom" width="12%">
<col align="center" valign="bottom" width="12%">
<col align="center" valign="bottom" width="12%">
<col align="center" valign="bottom" width="13%">
<thead><tr class="First Last">
<th align="center">Treatment<br>(Daily Dose)</th>
<th align="center">N</th>
<th align="center">Total-C</th>
<th align="center">LDL-C</th>
<th align="center"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></th>
<th align="center">TG</th>
<th align="center">HDL-C</th>
<th align="center">Non-HDL-C/ HDL-C</th>
</tr></thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>Significantly different from lovastatin, ANCOVA, p ≤0.05</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">†</a></dt>
<dd>A negative value for the 95% CI for the difference between treatments favors atorvastatin for all except HDL-C, for which a positive value favors atorvastatin. If the range does not include 0, this indicates a statistically significant difference.</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">‡</a></dt>
<dd>Significantly different from pravastatin, ANCOVA, p ≤0.05</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">§</a></dt>
<dd>Significantly different from simvastatin, ANCOVA, p ≤0.05</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Italics">Study 1</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">Atorvastatin 10 mg</td>
<td align="center">707</td>
<td align="center">-27<a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a>
</td>
<td align="center">-36<a href="#footnote-18" class="Sup">*</a>
</td>
<td align="center">-28<a href="#footnote-18" class="Sup">*</a>
</td>
<td align="center">-17<a href="#footnote-18" class="Sup">*</a>
</td>
<td align="center">+7</td>
<td align="center">-37<a href="#footnote-18" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left">Lovastatin 20 mg</td>
<td align="center">191</td>
<td align="center">-19</td>
<td align="center">-27</td>
<td align="center">-20</td>
<td align="center">-6</td>
<td align="center">+7</td>
<td align="center">-28</td>
</tr>
<tr>
<td align="left">95% CI for Diff<a name="footnote-reference-19" href="#footnote-19" class="Sup">†</a>
</td>
<td align="center"></td>
<td align="center">-9.2, -6.5</td>
<td align="center">-10.7, -7.1</td>
<td align="center">-10.0, -6.5</td>
<td align="center">-15.2, -7.1</td>
<td align="center">-1.7, 2.0</td>
<td align="center">-11.1, -7.1</td>
</tr>
<tr>
<td class="Toprule" align="left"><span class="Italics">Study 2</span></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
</tr>
<tr>
<td align="left">Atorvastatin 10 mg</td>
<td align="center">222</td>
<td align="center">-25<a name="footnote-reference-20" href="#footnote-20" class="Sup">‡</a>
</td>
<td align="center">-35<a href="#footnote-20" class="Sup">‡</a>
</td>
<td align="center">-27<a href="#footnote-20" class="Sup">‡</a>
</td>
<td align="center">-17<a href="#footnote-20" class="Sup">‡</a>
</td>
<td align="center">+6</td>
<td align="center">-36<a href="#footnote-20" class="Sup">‡</a>
</td>
</tr>
<tr>
<td align="left">Pravastatin 20 mg</td>
<td align="center">77</td>
<td align="center">-17</td>
<td align="center">-23</td>
<td align="center">-17</td>
<td align="center">-9</td>
<td align="center">+8</td>
<td align="center">-28</td>
</tr>
<tr>
<td align="left">95% CI for Diff<a href="#footnote-19" class="Sup">†</a>
</td>
<td align="center"></td>
<td align="center">-10.8, -6.1</td>
<td align="center">-14.5, -8.2</td>
<td align="center">-13.4, -7.4</td>
<td align="center">-14.1, -0.7</td>
<td align="center">-4.9, 1.6</td>
<td align="center">-11.5, -4.1</td>
</tr>
<tr>
<td class="Toprule" align="left"><span class="Italics">Study 3</span></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
</tr>
<tr>
<td align="left">Atorvastatin 10 mg</td>
<td align="center">132</td>
<td align="center">-29<a name="footnote-reference-21" href="#footnote-21" class="Sup">§</a>
</td>
<td align="center">-37<a href="#footnote-20" class="Sup">‡</a>
</td>
<td align="center">-34<a href="#footnote-20" class="Sup">‡</a>
</td>
<td align="center">-23<a href="#footnote-20" class="Sup">‡</a>
</td>
<td align="center">+7</td>
<td align="center">-39<a href="#footnote-20" class="Sup">‡</a>
</td>
</tr>
<tr>
<td align="left">Simvastatin 10 mg</td>
<td align="center">45</td>
<td align="center">-24</td>
<td align="center">-30</td>
<td align="center">-30</td>
<td align="center">-15</td>
<td align="center">+7</td>
<td align="center">-33</td>
</tr>
<tr class="Last">
<td align="left">95% CI for Diff<a href="#footnote-19" class="Sup">†</a>
</td>
<td align="center"></td>
<td align="center">-8.7, -2.7</td>
<td align="center">-10.1, -2.6</td>
<td align="center">-8.0, -1.1</td>
<td align="center">-15.1, -0.7</td>
<td align="center">-4.3, 3.9</td>
<td align="center">-9.6, -1.9</td>
</tr>
</tbody>
</table>
<p>The impact on clinical outcomes of the differences in lipid-altering effects between treatments shown in Table 10 is not known. Table 10 does not contain data comparing the effects of atorvastatin 10 mg and higher doses of lovastatin, pravastatin, and simvastatin. The drugs compared in the studies summarized in the table are not necessarily interchangeable.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.8"></a><a name="section-13.8"></a><p></p>
<h2>14.8	Atorvastatin for <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> (<span class="Italics">Fredrickson</span> Type IV)</h2>
<p class="First">The response to atorvastatin in 64 patients with isolated <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> treated across several clinical trials is shown in the table below (Table 11). For the atorvastatin-treated patients, median (min, max) baseline TG level was 565 (267–1502).</p>
<table width="85%">
<caption><span>Table 11. Combined Patients with Isolated Elevated TG: Median (min, max) Percentage Change From Baseline</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center">Placebo<br>(N=12)</th>
<th align="center">Atorvastatin 10 mg<br>(N=37)</th>
<th align="center">Atorvastatin 20 mg<br>(N=13)</th>
<th align="center">Atorvastatin 80 mg<br>(N=14)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td align="left">Triglycerides</td>
<td align="center">-12.4 (-36.6, 82.7)</td>
<td align="center">-41.0 (-76.2, 49.4)</td>
<td align="center">-38.7 (-62.7, 29.5)</td>
<td align="center">-51.8 (-82.8, 41.3)</td>
</tr>
<tr class="Botrule">
<td align="left">Total-C</td>
<td align="center">-2.3 (-15.5, 24.4)</td>
<td align="center">-28.2 (-44.9, -6.8)</td>
<td align="center">-34.9 (-49.6, -15.2)</td>
<td align="center">-44.4 (-63.5, -3.8)</td>
</tr>
<tr class="Botrule">
<td align="left">LDL-C</td>
<td align="center">3.6 (-31.3, 31.6)</td>
<td align="center">-26.5 (-57.7, 9.8)</td>
<td align="center">-30.4 (-53.9, 0.3)</td>
<td align="center">-40.5 (-60.6, -13.8)</td>
</tr>
<tr class="Botrule">
<td align="left">HDL-C</td>
<td align="center">3.8 (-18.6, 13.4)</td>
<td align="center">13.8 (-9.7, 61.5)</td>
<td align="center">11.0 (-3.2, 25.2)</td>
<td align="center">7.5 (-10.8, 37.2)</td>
</tr>
<tr class="Botrule">
<td align="left">VLDL-C</td>
<td align="center">-1.0 (-31.9, 53.2)</td>
<td align="center">-48.8 (-85.8, 57.3)</td>
<td align="center">-44.6 (-62.2, -10.8)</td>
<td align="center">-62.0 (-88.2, 37.6)</td>
</tr>
<tr class="Last">
<td align="left">non-HDL-C</td>
<td align="center">-2.8 (-17.6, 30.0)</td>
<td align="center">-33.0 (-52.1, -13.3)</td>
<td align="center">-42.7 (-53.7, -17.4)</td>
<td align="center">-51.5 (-72.9, -4.3)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.9"></a><a name="section-13.9"></a><p></p>
<h2>14.9	Atorvastatin for Dysbetalipoproteinemia (<span class="Italics">Fredrickson</span> Type III)</h2>
<p class="First">The results of an open-label crossover study of 16 patients (genotypes: 14 apo E2/E2 and 2 apo E3/E2) with dysbetalipoproteinemia <span class="Italics">(Fredrickson </span>Type III) are shown in the table below (Table 12).</p>
<table width="75%">
<caption><span>Table 12. Open-Label Crossover Study of 16 Patients with Dysbetalipoproteinemia (Fredrickson Type III)</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center"></th>
<th class="Botrule" align="center" colspan="2">Median % Change (min, max)</th>
</tr>
<tr class="Last">
<th align="left"></th>
<th align="center">Median (min, max) at Baseline (mg/dL)</th>
<th align="center">Atorvastatin 10 mg</th>
<th align="center">Atorvastatin 80 mg</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Toprule" align="left">Total-C</td>
<td class="Toprule" align="center">442 (225, 1320)</td>
<td class="Toprule" align="center">-37 (-85, 17)</td>
<td class="Toprule" align="center">-58 (-90, -31)</td>
</tr>
<tr class="Botrule">
<td align="left">Triglycerides</td>
<td align="center">678 (273, 5990)</td>
<td align="center">-39 (-92, -8)</td>
<td align="center">-53 (-95, -30)</td>
</tr>
<tr class="Botrule">
<td align="left">IDL-C + VLDL-C</td>
<td align="center">215 (111, 613)</td>
<td align="center">-32 (-76, 9)</td>
<td align="center">-63 (-90, -8)</td>
</tr>
<tr class="Last">
<td align="left">non-HDL-C</td>
<td align="center">411 (218, 1272)</td>
<td align="center">-43 (-87, -19)</td>
<td align="center">-64 (-92, -36)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.10"></a><a name="section-13.10"></a><p></p>
<h2>14.10	Atorvastatin for <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></h2>
<p class="First">In a study without a concurrent control group, 29 patients ages 6 to 37 years with homozygous FH received maximum daily doses of 20 to 80 mg of atorvastatin. The mean LDL-C reduction in this study was 18%. Twenty-five patients with a reduction in LDL-C had a mean response of 20% (range of 7% to 53%, median of 24%); the remaining 4 patients had 7% to 24% increases in LDL-C. Five of the 29 patients had absent LDL-receptor function. Of these, 2 patients also had a portacaval shunt and had no significant reduction in LDL-C. The remaining 3 receptor-negative patients had a mean LDL-C reduction of 22%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.11"></a><a name="section-13.11"></a><p></p>
<h2>14.11	Atorvastatin for <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients</h2>
<p class="First">In a double-blind, placebo-controlled study followed by an open-label phase, 187 boys and postmenarchal girls 10–17 years of age (mean age 14.1 years) with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (FH) or severe <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, were randomized to atorvastatin (n=140) or placebo (n=47) for 26 weeks and then all received atorvastatin for 26 weeks. Inclusion in the study required 1) a baseline LDL-C level ≥ 190 mg/dL or 2) a baseline LDL-C level ≥ 160 mg/dL and positive family history of FH or documented premature cardiovascular disease in a first or second-degree relative. The mean baseline LDL-C value was 218.6 mg/dL (range: 138.5–385.0 mg/dL) in the atorvastatin group compared to 230.0 mg/dL (range: 160.0–324.5 mg/dL) in the placebo group. The dosage of atorvastatin (once daily) was 10 mg for the first 4 weeks and uptitrated to 20 mg if the LDL-C level was &gt; 130 mg/dL. The number of atorvastatin-treated patients who required uptitration to 20 mg after Week 4 during the double-blind phase was 80 (57.1%).</p>
<p>Atorvastatin significantly decreased plasma levels of total-C, LDL-C, triglycerides, and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B during the 26-week double-blind phase (see<a href="#table13"> Table 13</a>).</p>
<a name="table13"></a><table width="80%">
<caption><span>Table 13. Lipid-Altering Effects of Atorvastatin in Adolescent Boys and Girls with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> or Severe <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> (Mean Percentage Change from Baseline at Endpoint in Intention-to-Treat Population)</span></caption>
<col align="left" valign="top" width="16%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="18%">
<thead><tr class="First Last">
<th align="left">DOSAGE</th>
<th align="center">N</th>
<th align="center">Total-C</th>
<th align="center">LDL-C</th>
<th align="center">HDL-C</th>
<th align="center">TG</th>
<th align="center"><span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">Apolipoprotein</span> B</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td align="left">Placebo</td>
<td align="center">47</td>
<td align="center">-1.5</td>
<td align="center">-0.4</td>
<td align="center">-1.9</td>
<td align="center">1.0</td>
<td align="center">0.7</td>
</tr>
<tr class="Last">
<td align="left">Atorvastatin</td>
<td align="center">140</td>
<td align="center">-31.4</td>
<td align="center">-39.6</td>
<td align="center">2.8</td>
<td align="center">-12.0</td>
<td align="center">-34.0</td>
</tr>
</tbody>
</table>
<p>The mean achieved LDL-C value was 130.7 mg/dL (range: 70.0–242.0 mg/dL) in the atorvastatin group compared to 228.5 mg/dL (range: 152.0–385.0 mg/dL) in the placebo group during the 26-week double-blind phase.</p>
<p>The safety and efficacy of doses above 20 mg have not been studied in controlled trials in children. The long-term efficacy of atorvastatin therapy in childhood to reduce morbidity and mortality in adulthood has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.12"></a><a name="section-13.12"></a><p></p>
<h2>14.12	Amlodipine Besylate and Atorvastatin Calcium Tablets for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> and <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></h2>
<p class="First">In a double-blind, placebo-controlled study, a total of 1660 patients with co-morbid <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> received once daily treatment with eight dose combinations of amlodipine and atorvastatin (5/10, 10/10, 5/20, 10/20, 5/40, 10/40, 5/80, or 10/80 mg), amlodipine alone (5 mg or 10 mg), atorvastatin alone (10 mg, 20 mg, 40 mg, or 80 mg), or placebo<span class="Bold">. </span>In addition to concomitant <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, 15% of the patients had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, 22% were smokers, and 14% had a positive family history of cardiovascular disease. At eight weeks, all eight combination-treatment groups of amlodipine and atorvastatin demonstrated statistically significant dose-related reductions in systolic blood pressure (SBP), diastolic blood pressure (DBP), and LDL-C compared to placebo, with no overall modification of effect of either component on SBP, DBP, and LDL-C (Table 14).</p>
<table width="75%">
<caption><span>Table 14. Effects of Amlodipine and Atorvastatin on Blood Pressure and LDL-C</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center">BP (mmHg)</th>
<th class="Rrule" align="center" colspan="5">Atorvastatin</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Amlodipine</th>
<th class="Rrule" align="center">0 mg</th>
<th class="Rrule" align="center">10 mg</th>
<th class="Rrule" align="center">20 mg</th>
<th class="Rrule" align="center">40 mg</th>
<th class="Rrule" align="center">80 mg</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">0 mg</span></td>
<td class="Rrule" align="center">—</td>
<td class="Botrule Rrule" align="center">-1.5/-0.8</td>
<td class="Botrule Rrule" align="center">-3.2/-0.6</td>
<td class="Botrule Rrule" align="center">-3.2/-1.8</td>
<td class="Botrule Rrule" align="center">-3.4/-0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">5 mg</span></td>
<td class="Rrule" align="center">-9.8/-4.3</td>
<td class="Rrule" align="center">-10.7/-4.9</td>
<td class="Rrule" align="center">-12.3/-6.1</td>
<td class="Rrule" align="center">-9.7/-4.0</td>
<td class="Rrule" align="center">-9.2/-5.1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="Bold">10 mg</span></td>
<td class="Rrule" align="center">-13.2/-7.1</td>
<td class="Rrule" align="center">-12.9/-5.8</td>
<td class="Rrule" align="center">-13.1/-7.3</td>
<td class="Rrule" align="center">-13.3/-6.5</td>
<td class="Rrule" align="center">-14.6/-7.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">LDL-C<br>(% change)</span></td>
<td class="Rrule Toprule" align="center" colspan="5" valign="middle"><span class="Bold">Atorvastatin</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">Amlodipine</span></td>
<td class="Rrule" align="center"><span class="Bold">0 mg</span></td>
<td class="Rrule" align="center"><span class="Bold">10 mg</span></td>
<td class="Rrule" align="center"><span class="Bold">20 mg</span></td>
<td class="Rrule" align="center"><span class="Bold">40 mg</span></td>
<td class="Rrule" align="center"><span class="Bold">80 mg</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">0 mg</span></td>
<td class="Rrule" align="center">—</td>
<td class="Botrule Rrule" align="center">-32.3</td>
<td class="Botrule Rrule" align="center">-38.4</td>
<td class="Botrule Rrule" align="center">-42.0</td>
<td class="Botrule Rrule" align="center">-46.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">5 mg</span></td>
<td class="Rrule" align="center">1.0</td>
<td class="Rrule" align="center">-37.6</td>
<td class="Rrule" align="center">-41.2</td>
<td class="Rrule" align="center">-43.8</td>
<td class="Rrule" align="center">-47.3</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left"><span class="Bold">10 mg</span></td>
<td class="Rrule" align="center">-1.4</td>
<td class="Rrule" align="center">-35.5</td>
<td class="Rrule" align="center">-37.5</td>
<td class="Rrule" align="center">-42.1</td>
<td class="Rrule" align="center">-48.0</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-14"></a><p></p>
<h1>15  REFERENCES</h1>
<p class="First"><span class="Sup">1</span> National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels in Children and Adolescents, <span class="Italics">Pediatrics.</span> 89(3):495–501. 1992.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Amlodipine besylate and atorvastatin calcium  tablets contain amlodipine besylate and atorvastatin calcium equivalent to amlodipine and atorvastatin in the dose strengths described below.</p>
<p>Amlodipine besylate and atorvastatin calcium tablets are differentiated by tablet color/size and are engraved with a unique number on one side. Combinations of atorvastatin with 2.5 mg amlodipine are round and film-coated white, combinations of atorvastatin with 5 mg amlodipine are oval and film-coated white, and combinations of atorvastatin with 10 mg amlodipine are oval and are film-coated blue. Amlodipine besylate and atorvastatin calcium tablets are supplied for oral administration in the following strengths and package configurations:</p>
<table width="85%">
<caption><span>Table 15. Amlodipine Besylate and Atorvastatin Calcium Tablets Packaging Configurations</span></caption>
<col align="left" valign="bottom" width="20%">
<col align="left" valign="bottom" width="26%">
<col align="left" valign="bottom" width="14%">
<col align="left" valign="bottom" width="14%">
<col align="left" valign="bottom" width="13%">
<col align="left" valign="bottom" width="13%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="6">Amlodipine Besylate/Atorvastatin Calcium Tablets</th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Package Configuration</th>
<th class="Rrule" align="left">Tablet Strength (amlodipine besylate/ atorvastatin calcium) mg</th>
<th class="Rrule" align="left">NDC #</th>
<th class="Rrule" align="left">Engraving</th>
<th class="Rrule" align="left">Tablet Color</th>
<th class="Rrule" align="left">Tablet Shape</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Bottle of 30</td>
<td class="Rrule" align="left">2.5/10</td>
<td class="Rrule" align="left">63304-501-30</td>
<td class="Rrule" align="left">CDT 251</td>
<td class="Rrule" align="left">White</td>
<td class="Rrule" align="left">Oval</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Bottle of 30</td>
<td class="Rrule" align="left">2.5/20</td>
<td class="Rrule" align="left">63304-502-30</td>
<td class="Rrule" align="left">CDT 252</td>
<td class="Rrule" align="left">White</td>
<td class="Rrule" align="left">Oval</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Bottle of 30</td>
<td class="Rrule" align="left">2.5/40</td>
<td class="Rrule" align="left">63304-503-30</td>
<td class="Rrule" align="left">CDT 254</td>
<td class="Rrule" align="left">White</td>
<td class="Rrule" align="left">Oval</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Bottle of 30</td>
<td class="Rrule" align="left">5/10</td>
<td class="Rrule" align="left">63304-587-30</td>
<td class="Rrule" align="left">AAT 051</td>
<td class="Rrule" align="left">White</td>
<td class="Rrule" align="left">Oval</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Bottle of 30</td>
<td class="Rrule" align="left">5/20</td>
<td class="Rrule" align="left">63304-588-30</td>
<td class="Rrule" align="left">AAT 052</td>
<td class="Rrule" align="left">White</td>
<td class="Rrule" align="left">Oval</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Bottle of 30</td>
<td class="Rrule" align="left">5/40</td>
<td class="Rrule" align="left">63304-589-30</td>
<td class="Rrule" align="left">AAT 054</td>
<td class="Rrule" align="left">White</td>
<td class="Rrule" align="left">Oval</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Bottle of 30</td>
<td class="Rrule" align="left">5/80</td>
<td class="Rrule" align="left">63304-499-30</td>
<td class="Rrule" align="left">AAT 058</td>
<td class="Rrule" align="left">White</td>
<td class="Rrule" align="left">Oval</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Bottle of 30</td>
<td class="Rrule" align="left">10/10</td>
<td class="Rrule" align="left">63304-590-30</td>
<td class="Rrule" align="left">AAT 101</td>
<td class="Rrule" align="left">Blue</td>
<td class="Rrule" align="left">Oval</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Bottle of 30</td>
<td class="Rrule" align="left">10/20</td>
<td class="Rrule" align="left">63304-591-30</td>
<td class="Rrule" align="left">AAT 102</td>
<td class="Rrule" align="left">Blue</td>
<td class="Rrule" align="left">Oval</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Bottle of 30</td>
<td class="Rrule" align="left">10/40</td>
<td class="Rrule" align="left">63304-500-30</td>
<td class="Rrule" align="left">AAT 104</td>
<td class="Rrule" align="left">Blue</td>
<td class="Rrule" align="left">Oval</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Bottle of 30</td>
<td class="Rrule" align="left">10/80</td>
<td class="Rrule" align="left">63304-603-30</td>
<td class="Rrule" align="left">AAT 108</td>
<td class="Rrule" align="left">Blue</td>
<td class="Rrule" align="left">Oval</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.1"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (Patient Information).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First"><span class="Bold">Information for Patients</span></p>
<p>Because of the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with statins, the drug class to which atorvastatin belongs, advise patients to report unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</p>
<p>Advise patients taking atorvastatin that <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is a chronic condition and they should adhere to their medication along with their National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Education Program (NCEP)-recommended diet, a regular exercise program as appropriate, and periodic testing of a fasting lipid panel to determine goal attainment.</p>
<p>Advise patients about substances they should not take concomitantly with atorvastatin <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>. Patients should inform other healthcare professionals prescribing a new medication that they are taking amlodipine besylate and atorvastatin calcium tablets.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span>: </span>Advise patients starting therapy with amlodipine besylate and atorvastatin calcium tablets of the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and to report promptly any unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if these muscle signs or symptoms persist after discontinuing amlodipine besylate and atorvastatin calcium tablets. The risk of this occurring is increased when taking certain types of medication or consuming larger quantities (&gt;1 liter) of grapefruit juice. They should discuss all medication, both prescription and over the counter, with their healthcare professional.</p>
<p><span class="Bold">Liver Enzymes: </span>Advise patients treated with amlodipine besylate and atorvastatin calcium tablets to report promptly any symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine, or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
<p><span class="Bold">Pregnancy: </span>Women of childbearing age should be advised to use an effective method of birth control to prevent pregnancy while using amlodipine besylate and atorvastatin calcium tablets. Discuss future pregnancy plans with your patients, and discuss when to stop amlodipine besylate and atorvastatin calcium tablets if they are trying to conceive. Patients should be advised that if they become pregnant, they should stop taking amlodipine besylate and atorvastatin calcium tablets and call their healthcare professional.</p>
<p><span class="Bold">Breast-feeding: </span>Women who are breast-feeding should be advised to not use amlodipine besylate and atorvastatin calcium tablets. Patients who have a lipid disorder and are breast-feeding should be advised to discuss the options with their healthcare professional.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<p class="First">Distributed by:<br>Ranbaxy Pharmaceuticals Inc.<br>Jacksonville, FL 32257 USA</p>
<p>LAB-0532-7.0</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">AMLODIPINE BESYLATE/ATORVASTATIN CALCIUM TABLETS</span></p>
<p>Read the patient information that comes with amlodipine besylate and atorvastatin calcium tablets before you start taking it, and each time you get a refill. There may be new information. This information does not replace talking with your doctor about your condition or treatment. If you have any questions about amlodipine besylate and atorvastatin calcium tablets, ask your doctor or pharmacist.</p>
<p><span class="Bold">What are amlodipine besylate and atorvastatin calcium tablets?</span></p>
<p>Amlodipine besylate and atorvastatin calcium tablets are a prescription drug that combines amlodipine besylate and atorvastatin calcium in one pill.</p>
<p><span class="Bold">Amlodipine besylate and atorvastatin calcium tablets are used in adults who need both amlodipine besylate and atorvastatin calcium.</span></p>
<p>Amlodipine besylate is used to treat:</p>
<ul>
<li>High blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) and</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> (angina) and</li>
<li>Blocked arteries of the heart (<span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>)</li>
</ul>
<p>Atorvastatin calcium is used to lower the levels of "bad" <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides in your blood. It can also raise the levels of "good" <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.</p>
<p>Atorvastatin calcium is also used to lower the risk for <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, certain types of heart surgery, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> in patients who have heart disease or risk factors for heart disease such as:</p>
<ul class="Disc"><li>age, smoking, high blood pressure, low levels of "good" <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, heart disease in the family.</li></ul>
<p>Atorvastatin calcium can lower the risk for <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and risk factors such as:</p>
<ul class="Disc"><li>diabetic eye or kidney problems, smoking, or high blood pressure.</li></ul>
<p>Amlodipine besylate and atorvastatin calcium tablets have not been studied in children.</p>
<p><span class="Bold">Who should not use amlodipine besylate and atorvastatin calcium tablets?</span></p>
<p><span class="Bold Underline">Do not use amlodipine besylate and atorvastatin calcium tablets if you</span><span class="Underline">:</span></p>
<ul>
<li>Are pregnant or think you may be pregnant, or are planning to become pregnant. Amlodipine besylate and atorvastatin calcium tablets may harm your unborn baby. If you get pregnant, stop taking amlodipine besylate and atorvastatin calcium tablets and call your doctor right away.</li>
<li>Are breastfeeding. Amlodipine besylate and atorvastatin calcium tablets can pass into your breast milk and may harm your baby. Do not breastfeed if you take amlodipine besylate and atorvastatin calcium tablets.</li>
<li>Have liver problems.</li>
<li>Are allergic to anything in amlodipine besylate and atorvastatin calcium tablets. The active ingredients are atorvastatin calcium and amlodipine besylate. See the end of this leaflet for a complete list of ingredients.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking amlodipine besylate and atorvastatin calcium tablets?</span></p>
<p><span class="Bold">Tell your doctor about all of your health conditions, including, if you have:</span></p>
<ul>
<li>heart disease</li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li>thyroid problems</li>
<li>kidney problems</li>
<li>or drink more than 2 glasses of alcohol daily</li>
</ul>
<p>Tell your doctor about all the medicines you take including prescription and nonprescription medicines, vitamins, and herbal supplements. Amlodipine besylate and atorvastatin calcium tablets and some other medicines can interact, causing serious side effects. Especially tell your doctor if you take medicines for:</p>
<table class="Noautorules" width="50%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul>
<li>your immune system</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></li>
<li><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></li>
</ul></td>
<td align="left"><ul>
<li>birth control</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></li>
<li>HIV (AIDS)</li>
</ul></td>
</tr></tbody>
</table>
<p>You can use nitroglycerin and amlodipine besylate and atorvastatin calcium tablets together. If you take nitroglycerin for <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (angina), do not stop taking it while taking amlodipine besylate and atorvastatin calcium tablets.</p>
<p>Know all the medicines you take. Keep a list of them with you to show your doctor and pharmacist.</p>
<p><span class="Bold">How should I take amlodipine besylate and atorvastatin calcium tablets?</span></p>
<ul>
<li>Take amlodipine besylate and atorvastatin calcium tablets once a day, exactly as your doctor tells you. Do not change your dose or stop amlodipine besylate and atorvastatin calcium tablets without talking to your doctor.</li>
<li>Take amlodipine besylate and atorvastatin calcium tablets each day at any time of day, at about the same time each day. Amlodipine besylate and atorvastatin calcium tablets can be taken with or without food.</li>
<li>Do not break the tablets before taking them. Talk to your doctor if you have a problem swallowing pills.</li>
<li>Your doctor should start you on a low-fat diet before giving you amlodipine besylate and atorvastatin calcium tablets. Stay on this low-fat diet when you take amlodipine besylate and atorvastatin calcium tablets.</li>
<li>If you miss a dose, take it as soon as you remember. Do not take amlodipine besylate and atorvastatin calcium tablets if it has been more than 12 hours since your missed dose. Just take the next dose at your regular time. Do not take 2 doses of amlodipine besylate and atorvastatin calcium tablets at the same time.</li>
<li> If too much amlodipine besylate and atorvastatin calcium tablets are taken by <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, call your doctor or poison control center, or go to the nearest emergency room.</li>
</ul>
<p><span class="Bold">What should I avoid while taking amlodipine besylate and atorvastatin calcium tablets?</span></p>
<ul>
<li>Avoid getting pregnant. If you get pregnant, stop taking amlodipine besylate and atorvastatin calcium tablets right away and call your doctor.</li>
<li>Do not breastfeed. Amlodipine besylate and atorvastatin calcium tablets can pass into your breast milk and may harm your baby.</li>
</ul>
<p><span class="Bold">What are possible side effects of amlodipine besylate and atorvastatin calcium tablets?</span></p>
<p><span class="Bold">Amlodipine besylate and atorvastatin calcium tablets can cause serious side effects. These side effects happen only to a small number of people. Your doctor can monitor you for them. These side effects usually go away if your dose is lowered or amlodipine besylate and atorvastatin calcium tablets are stopped. These serious side effects include:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Muscle problems. </span>Amlodipine besylate and atorvastatin calcium tablets can cause serious muscle problems that can lead to kidney problems, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>. You have a higher chance for muscle problems if you are taking certain other medicines with amlodipine besylate and atorvastatin calcium tablets.</li>
<li>
<span class="Bold">Liver problems.</span> Your doctor should do blood tests to check your liver before you start taking amlodipine besylate and atorvastatin calcium tablets and if you have symptoms of liver problems while you take amlodipine besylate and atorvastatin calcium tablets. Call your doctor right away if you have the following symptoms of liver problems: 						<ul class="Disc">
<li>feel tired or weak</li>
<li>loss of appetite</li>
<li>upper belly <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li>dark amber colored urine</li>
<li>yellowing of your skin or the whites of your eyes</li>
</ul>
</li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></span></li>
</ul>
<p><span class="Bold">Call your doctor right away if:</span></p>
<ul class="Disc">
<li>you have muscle problems like <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that happen without a good reason, especially if you also have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or feel more tired than usual. This may be an early sign of a rare muscle problem.</li>
<li>muscle problems that do not go away even after your doctor has advised you to stop taking amlodipine besylate and atorvastatin calcium tablets. Your doctor may do further tests to diagnose the cause of your muscle problems.</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing which may require treatment right away</li>
<li>you have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>you are passing brown or dark-colored urine</li>
<li>you feel more tired than usual</li>
<li>your skin and white of your eyes get yellow</li>
<li>you have <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span></li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> that does not go away or gets worse. </span>Sometimes when you start amlodipine besylate and atorvastatin calcium tablets or increase your dose, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> can get worse or a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> can happen. If this happens, call your doctor or go to the emergency room right away.</li>
</ul>
<p>Common side effects of amlodipine besylate and atorvastatin calcium tablets include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of your legs or ankles</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">Upset stomach</span></li>
<li>Muscle and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></li>
<li>Alterations in some laboratory blood tests</li>
</ul>
<p>Additional side effects have been reported: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, tendon problems, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</p>
<p>Talk to your doctor or pharmacist about side effects that bother you or do not go away.</p>
<p>There are other side effects of amlodipine besylate and atorvastatin calcium tablets. Ask your doctor or pharmacist for a complete list.</p>
<p><span class="Bold">How do I store amlodipine besylate and atorvastatin calcium tablets?</span></p>
<ul>
<li>Store amlodipine besylate and atorvastatin calcium tablets at room temperature, 68°F to 77°F (20°C to 25°C).</li>
<li>Do not keep medicine that is out-of-date or that you no longer need.<br><span class="Bold">Keep amlodipine besylate and atorvastatin calcium tablets and all medicines out of the reach of children. </span>Keep medicines in places where children cannot get it.</li>
</ul>
<p><span class="Bold">General information about amlodipine besylate and atorvastatin calcium tablets</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use amlodipine besylate and atorvastatin calcium tablets for a condition for which it was not prescribed. Do not give amlodipine besylate and atorvastatin calcium tablets to other people, even if they have the same problem you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about amlodipine besylate and atorvastatin calcium tablets. If you want more information, talk with your doctor. Ask your doctor or pharmacist for information about amlodipine besylate and atorvastatin calcium tablets written for health professionals. You can also call Ranbaxy at 1-888-RANBAXY (1-888-726-2299).</p>
<p><span class="Bold Underline">What is high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)?</span></p>
<p>You have high blood pressure when the force of blood against the walls of your arteries stays high. This can damage your heart and other parts of your body. Drugs that lower blood pressure lower your risk of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</p>
<p><span class="Bold Underline">What is angina (<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>)?</span></p>
<p>Angina is a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that keeps coming back when part of your heart does not get enough blood. It feels like something is pressing or squeezing your chest under the breastbone. Sometimes you can feel it in your shoulders, arms, neck, jaw, or back.</p>
<p><span class="Bold Underline">What is <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>?</span></p>
<p><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> is a fat-like substance made in your body. It is also found in foods. You need some <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> for good health, but too much is not good for you. <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> can clog your blood vessels.</p>
<p><span class="Bold Underline">What is a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>?</span></p>
<p>A <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> occurs when heart muscle does not get enough blood. Symptoms include <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, trouble breathing, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Heart muscle cells may be damaged or die. The heart cannot pump well or may stop beating.</p>
<p><span class="Bold Underline">What is a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>?</span></p>
<p>A <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occurs when nerve cells in the brain do not get enough blood. The cells may be damaged or die. The damaged cells may cause <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or problems speaking or thinking.</p>
<p><span class="Bold">WHAT ARE THE INGREDIENTS IN AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM TABLETS?</span></p>
<p><span class="Bold">Active ingredients:</span> amlodipine besylate, atorvastatin calcium</p>
<p><span class="Bold">Inactive ingredients:</span> calcium carbonate, croscarmellose sodium, microcrystalline cellulose, pregelatinized starch, polysorbate 80, hydroxypropyl cellulose, purified water, colloidal silicon dioxide (anhydrous), magnesium stearate</p>
<p><span class="Bold">Film coating: </span>Opadry® II White 85F28751 (polyvinyl alcohol, titanium dioxide, PEG 3000, and talc) or Opadry® II Blue 85F10919 (polyvinyl alcohol, titanium dioxide, PEG 3000, talc, and FD&amp;C blue #2)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-19"></a><p></p>
<p class="First">Distributed by:<br>Ranbaxy Pharmaceuticals Inc.<br>Jacksonville, FL 32257 USA</p>
<p>LAB-0533-3.0<br>January 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 2.5 mg/10 mg Tablet Label</span></p>
<p><span class="Bold">R RANBAXY</span></p>
<p><span class="Bold">NDC 63304-501-30</span></p>
<p><span class="Bold">AMLODIPINE<br>BESYLATE/<br>ATORVASTATIN<br>CALCIUM<br>TABLETS<br>2.5 mg/10 mg*</span></p>
<p><span class="Bold">Rx only<br>30 Tablets</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2.5 mg/10 mg Tablet Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-08.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 2.5 mg/20 mg Tablet Label</span></p>
<p><span class="Bold">R RANBAXY</span></p>
<p><span class="Bold">NDC 63304-502-30</span></p>
<p><span class="Bold">AMLODIPINE<br>BESYLATE/<br>ATORVASTATIN<br>CALCIUM<br>TABLETS<br>2.5 mg/20 mg*</span></p>
<p><span class="Bold">Rx only<br>30 Tablets</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2.5 mg/20 mg Tablet Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-09.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-22"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 2.5 mg/40 mg Tablet Label</span></p>
<p><span class="Bold">R RANBAXY</span></p>
<p><span class="Bold">NDC 63304-503-30</span></p>
<p><span class="Bold">AMLODIPINE<br>BESYLATE/<br>ATORVASTATIN<br>CALCIUM<br>TABLETS<br>2.5 mg/40 mg*</span></p>
<p><span class="Bold">Rx only<br>30 Tablets</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2.5 mg/40 mg Tablet Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-10.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-23"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 5 mg/10 mg Tablet Label</span></p>
<p><span class="Bold">R RANBAXY</span></p>
<p><span class="Bold">NDC 63304-587-30</span></p>
<p><span class="Bold">AMLODIPINE<br>BESYLATE/<br>ATORVASTATIN<br>CALCIUM<br>TABLETS<br>5 mg/10 mg*</span></p>
<p><span class="Bold">Rx only<br>30 Tablets</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg/10 mg Tablet Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-11.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-24"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 5 mg/20 mg Tablet Label</span></p>
<p><span class="Bold">R RANBAXY</span></p>
<p><span class="Bold">NDC 63304-588-30</span></p>
<p><span class="Bold">AMLODIPINE<br>BESYLATE/<br>ATORVASTATIN<br>CALCIUM<br>TABLETS<br>5 mg/20 mg*</span></p>
<p><span class="Bold">Rx only<br>30 Tablets</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg/20 mg Tablet Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-12.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-25"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 5 mg/40 mg Tablet Label</span></p>
<p><span class="Bold">R RANBAXY</span></p>
<p><span class="Bold">NDC 63304-589-30</span></p>
<p><span class="Bold">AMLODIPINE<br>BESYLATE/<br>ATORVASTATIN<br>CALCIUM<br>TABLETS<br>5 mg/40 mg*</span></p>
<p><span class="Bold">Rx only<br>30 Tablets</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg/40 mg Tablet Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-13.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-26"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 5 mg/80 mg Tablet Label</span></p>
<p><span class="Bold">R RANBAXY</span></p>
<p><span class="Bold">NDC 63304-499-30</span></p>
<p><span class="Bold">AMLODIPINE<br>BESYLATE/<br>ATORVASTATIN<br>CALCIUM<br>TABLETS<br>5 mg/80 mg*</span></p>
<p><span class="Bold">Rx only<br>30 Tablets</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg/80 mg Tablet Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-14.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-27"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 mg/10 mg Tablet Label</span></p>
<p><span class="Bold">R RANBAXY</span></p>
<p><span class="Bold">NDC 63304-590-30</span></p>
<p><span class="Bold">AMLODIPINE<br>BESYLATE/<br>ATORVASTATIN<br>CALCIUM<br>TABLETS<br>10 mg/10 mg*</span></p>
<p><span class="Bold">Rx only<br>30 Tablets</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg/10 mg Tablet Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-15.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-28"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 mg/20 mg Tablet Label</span></p>
<p><span class="Bold">R RANBAXY</span></p>
<p><span class="Bold">NDC 63304-591-30</span></p>
<p><span class="Bold">AMLODIPINE<br>BESYLATE/<br>ATORVASTATIN<br>CALCIUM<br>TABLETS<br>10 mg/20 mg*</span></p>
<p><span class="Bold">Rx only<br>30 Tablets</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg/20 mg Tablet Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-16.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-29"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 mg/40 mg Tablet Label</span></p>
<p><span class="Bold">R RANBAXY</span></p>
<p><span class="Bold">NDC 63304-500-30</span></p>
<p><span class="Bold">AMLODIPINE<br>BESYLATE/<br>ATORVASTATIN<br>CALCIUM<br>TABLETS<br>10 mg/40 mg*</span></p>
<p><span class="Bold">Rx only<br>30 Tablets</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg/40 mg Tablet Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-17.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-30"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 mg/80 mg Tablet Label</span></p>
<p><span class="Bold">R RANBAXY</span></p>
<p><span class="Bold">NDC 63304-592-30</span></p>
<p><span class="Bold">AMLODIPINE<br>BESYLATE/<br>ATORVASTATIN<br>CALCIUM<br>TABLETS<br>10 mg/80 mg*</span></p>
<p><span class="Bold">Rx only<br>30 Tablets</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg/80 mg Tablet Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-18.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-31"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 mg/80 mg Tablet Label</span></p>
<p><span class="Bold">R RANBAXY</span></p>
<p><span class="Bold">NDC 63304-603-30</span></p>
<p><span class="Bold">AMLODIPINE<br>BESYLATE/<br>ATORVASTATIN<br>CALCIUM<br>TABLETS<br>10 mg/80 mg*</span></p>
<p><span class="Bold">Rx only<br>30 Tablets</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg/80 mg Tablet Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94&amp;name=amlodipine-19.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-501</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">2.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM TRIHYDRATE</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CDT;251</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-501-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA021540</td>
<td class="formItem">12/06/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-502</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">2.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM TRIHYDRATE</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CDT;252</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-502-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA021540</td>
<td class="formItem">12/06/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-503</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">2.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM TRIHYDRATE</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CDT;254</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-503-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA021540</td>
<td class="formItem">12/06/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-587</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM TRIHYDRATE</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AAT;051</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-587-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA021540</td>
<td class="formItem">12/06/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-588</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM TRIHYDRATE</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AAT;052</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-588-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA021540</td>
<td class="formItem">12/06/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-589</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM TRIHYDRATE</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AAT;054</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-589-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA021540</td>
<td class="formItem">01/30/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-499</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM TRIHYDRATE</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN</td>
<td class="formItem">80 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AAT;058</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-499-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA021540</td>
<td class="formItem">12/06/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-590</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM TRIHYDRATE</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AAT;101</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-590-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA021540</td>
<td class="formItem">12/06/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-591</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM TRIHYDRATE</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AAT;102</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-591-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA021540</td>
<td class="formItem">12/06/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-500</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM TRIHYDRATE</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AAT;104</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-500-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA021540</td>
<td class="formItem">12/06/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-603</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM TRIHYDRATE</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN</td>
<td class="formItem">80 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AAT;108</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-603-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA021540</td>
<td class="formItem">12/06/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Ranbaxy Pharmaceuticals Inc
							(937890044)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Pfizer Inc (113480771)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Ireland Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">989811526</td>
<td class="formItem">API MANUFACTURE(63304-603, 63304-500, 63304-591, 63304-590, 63304-499, 63304-589, 63304-588, 63304-587, 63304-503, 63304-502, 63304-501)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Ireland Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">896090987</td>
<td class="formItem">API MANUFACTURE(63304-603, 63304-500, 63304-591, 63304-590, 63304-499, 63304-589, 63304-588, 63304-587, 63304-503, 63304-502, 63304-501)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Manufacturing Deutschland GmbH (Betriebsstätte Freiburg)</td>
<td class="formItem"></td>
<td class="formItem">341970073</td>
<td class="formItem">API MANUFACTURE(63304-603, 63304-500, 63304-591, 63304-590, 63304-499, 63304-589, 63304-588, 63304-587, 63304-503, 63304-502, 63304-501), MANUFACTURE(63304-603, 63304-500, 63304-591, 63304-590, 63304-499, 63304-589, 63304-588, 63304-587, 63304-503, 63304-502, 63304-501), PACK(63304-603, 63304-500, 63304-591, 63304-590, 63304-499, 63304-589, 63304-588, 63304-587, 63304-503, 63304-502, 63304-501), REPACK(63304-603, 63304-500, 63304-591, 63304-590, 63304-499, 63304-589, 63304-588, 63304-587, 63304-503, 63304-502, 63304-501)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmacia and Upjohn Company</td>
<td class="formItem"></td>
<td class="formItem">829076566</td>
<td class="formItem">PACK(63304-603, 63304-500, 63304-591, 63304-590, 63304-499, 63304-589, 63304-588, 63304-587, 63304-503, 63304-502, 63304-501)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Pharmaceuticals LLC</td>
<td class="formItem"></td>
<td class="formItem">829084545</td>
<td class="formItem">API MANUFACTURE(63304-603, 63304-500, 63304-591, 63304-590, 63304-499, 63304-589, 63304-588, 63304-587, 63304-503, 63304-502, 63304-501)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Pharmaceuticals LLC</td>
<td class="formItem"></td>
<td class="formItem">829084552</td>
<td class="formItem">PACK(63304-603, 63304-500, 63304-591, 63304-590, 63304-499, 63304-589, 63304-588, 63304-587, 63304-503, 63304-502, 63304-501)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NEOLPHARMA, INC.</td>
<td class="formItem"></td>
<td class="formItem">078709787</td>
<td class="formItem">PACK(63304-603, 63304-500, 63304-591, 63304-590, 63304-499, 63304-589, 63304-588, 63304-587, 63304-503, 63304-502, 63304-501)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Ireland Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">985052076</td>
<td class="formItem">API MANUFACTURE(63304-603, 63304-500, 63304-591, 63304-590, 63304-499, 63304-589, 63304-588, 63304-587, 63304-503, 63304-502, 63304-501)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>637c6e1b-099a-4f59-8a06-ca38456862a7</div>
<div>Set id: d2d28679-a01b-4e63-90e2-d5c23b393c94</div>
<div>Version: 7</div>
<div>Effective Time: 20140304</div>
</div>
</div> <div class="DistributorName">Ranbaxy Pharmaceuticals Inc</div></p>
</body></html>
